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Abstract 
Scabies and associated bacterial skin infections are highly prevalent in the tropics and a major 
disease burden in Australian Aboriginal communities. It is believed that damage to the upper 
layers of the human skin as a result of the burrowing action of scabies mites provides an entry 
point for bacterial pathogens. One of the most frequently associated bacterial pathogen with 
scabies infections is Streptococcus pyogenes or Group A Streptococcus (GAS). This is of 
serious concern because of the potentially fatal secondary diseases associated with GAS 
infections such as acute rheumatic fever (ARF), rheumatic heart disease (RHD) and post-
streptococcal glomerulonephritis (PSGN). In Indigenous Australian communities the 
prevalence of ARF/RHD is amongst the highest rates reported globally. Traditiona lly, 
ARF/RHD was attributed to GAS infections of the throat; however, GAS throat infections are 
relatively rare in many communities that have high rates of ARF/RHD, while GAS skin 
infections are common in these communities. Previous studies have shown that scabies mites 
secrete proteins that inhibit the host’s immune defence processes, thereby potentially 
promoting the survival of pathogenic bacteria in these hosts. These initial studies indicated that 
scabies mite infections may play important roles in the establishment, proliferation and 
transmission of a range of microbial pathogens. This project aimed to address the mechanisms 
by which the scabies mite complement inhibitors, inactivated protease paralogue - serine I1 
(SMIPP-S I1) and serpin B4 (SMS B4) - promote the recovery of GAS. A variety of clinica l 
GAS strains were examined in this study, including S. pyogenes 88-30; isolated from a scabies 
skin lesion of an Aboriginal Australian in the Northern Territory. The methodology included 
global bactericidal assays, deposition assays and phagocytosis assays to demonstrate the effects 
of the mite complement inhibitors on complement killing of bacteria, complement deposition 
on the bacteria surface and phagocytosis of bacteria, respectively. It was found that both 
SMIPP-S I1 and SMS B4 proteins promoted the growth of S. pyogenes in a concentration-
dependent manner, and that these effects were not GAS strain-specific. The scabies mite 
complement inhibitors were found to interfere with the activation and progression of the 
Classical and Alternative pathways of the complement system. Most notably, both mite 
complement inhibitors reduced the opsonisation of GAS strains by decreasing the deposition 
of C3b on the bacterial cell surface. These findings indicate that scabies mite complement 
inhibitors may play key roles in establishing pyoderma, or purulent skin diseases caused by 
infections with pathogens such as S. pyogenes. This novel insight at a molecular level into the 
pathogenesis of scabies and secondary bacterial infections may provide a new explanation why 
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patients infected with scabies are predisposed to secondary bacterial infections, potentially 
leading to severe and fatal secondary diseases such as PSGN, ARF and RHD. Tabl e of  Cont ent s  
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1.1 The scabies mite 
The scabies mite Sarcoptes scabiei, is an ectoparasite responsible for the infectious, 
inflammatory skin disease known as scabies in humans and mange in animals. S. scabiei infects 
a wide range of organisms, such as humans, rodents and livestock (Arlian et al., 1984). S. 
scabiei is comprised of many varieties (var,) of the same species infecting specific hosts, with 
Sarcoptes scabiei var. hominis afflicting humans (Hengge et al., 2006). Rare cross-infection of 
scabies sub-species between humans and other animal hosts can occur, though this is mostly 
self-limiting (Arlian et al., 1984). The lifecycle of the scabies mite spans 9 – 13 days on average 
occurring over 4 life stages:  an egg, larval, nymph and adult stage, as represented in Figure 1. 
Adult mites vary in size, with adult females ranging from approximately 0.30 – 0.45 mm long, 
and the smaller males generally ranging from 0.20 – 0.25 mm in length (Burgess, 1994).  
 
Figure 1. The lifecycle of Sarcoptes scabiei.                                                                                  
Image courtesy of the Centers for Disease Control and Prevention, USA (CDC, 2010)  
 
S. scabiei is an obligate parasite, with a limited ability to survive independently of its host for 
up to 36 hours at average room temperature (RT) and humidity, and sometimes longer at lower 
temperatures and higher humidity (Arlian et al., 1984). The pathogenesis of scabies disease 
commences with the burrowing of the mite into the upper epidermis of its host, an infect ion 
that can lead to two distinct clinical presentations - “ordinary” scabies and crusted (Norwegian) 
scabies (Burgess, 1994). 
3 
 
1.2 Clinical presentations of scabies 
The most common clinical presentation of scabies, the ordinarily termed "scabies", appears as 
a papular or vesicular rash, in which around 10-15 mites are present on the infected host. 
Common anatomical sites of scabies colonisation, as shown in Figure 2, are in the folds and 
moist areas of the body, including around the elbows, arm pits, pubic region, buttocks and 
webbing of hands (Jackson et al., 2007). The second form of the disease, crusted (Norwegian) 
scabies, is a relatively rare condition, mostly seen in infected immunocompromised 
individuals. It is characterised by the formation of  hyperkeratotic skin crusts, that may contain 
up to millions of mites on a single host, generally on the hands and feet, though in some cases 
involving the whole body (Walton et al., 2008). The general symptoms of scabies infect ions 
include intense itching, disrupted sleep, and anxiety due to social stigma, resulting in 
significantly reduced quality of life for those infected (Jackson et al., 2007). The crusted form 
of the disease is extremely difficult to treat and is also highly contagious (Walton et al., 2008). 
Therefore, it has been proposed that crusted scabies patients may be acting as ‘core 
transmitters’, by causing reinfections of communities where ordinary scabies has been 
successfully cleared (Walton et al., 1999). 
 
Figure 2. Common anatomical sites of scabies infections in humans .                                         
The areas highlighted dark pink are the most prevalent sites of scabies colonisation - the wrist 
and webbing of the hands. Image courtesy of the Centers for Disease Control and Prevention, 
USA (CDC, 2010). 
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1.3 Epidemiology of scabies 
Scabies is a ubiquitous disease, with an estimated 300 million infections per annum worldwide 
(Haidan et al., 2000). Transmission occurs by person-to-person contact, or by infected persons 
interacting with fomites such as clothing, bedding or shared household items that are 
contaminated with mites or mite eggs that were shed from infected individuals (Mellanby, 
1944). There are a range of proposed factors that are believed to influence the risk of 
contracting scabies, including: age, nutritional status, living conditions and climate (Wong et 
al., 2001). Endemic scabies is commonly found within populations that are subject to 
overcrowding, namely developing countries, low socioeconomic communities and global 
regions experiencing significant environmental stressors such as during times of war and 
environmental disasters (Wong et al., 2001). It is one of the most common skin diseases in the 
developing world, with rates of 18 – 42% reported in the Pacific Islands and up to 70% in India 
(Chakravarty et al., 2014). While the rate of scabies in developed nations is considerably low, 
sporadic epidemic outbreaks of scabies are still reported in hospitals, nursing homes, prisons 
and schools where close contact and sharing of furniture and other potential infected fomites 
occurs (Bouvresse & Chosidow, 2010; Lassa et al., 2011; Stoevesandt et al., 2012). Within the 
Australian Indigenous community, scabies has a high incidence, particularly in tropical and 
remote communities of northern Australia; where up to 70% of children will contract scabies 
before reaching 2 years of age (Clucas et al., 2008). These same regions are also commonly 
reported as having high rates of bacterial co-infections (Steer et al., 2009).  
 
1.4 Diagnosis, treatment and control of scabies 
There is no current standard for scabies diagnosis in humans, which leads to many 
misdiagnoses, as initial clinical presentations may represent a range of other common skin 
conditions, such as tinea, dermatitis and eczema (Walton & Currie, 2007). Scabies can be 
treated by topical or oral acaricides; ordinary scabies is most commonly treated with the use of 
topical acaricides such as 5% permethrin, 10-25% benzyl benzoate, 10% crotamiton and 0.3-
1% lindane (Currie & McCarthy, 2010). Ivermectin is the only oral acaricide approved for 
treatment of human infections and it is commonly reserved for the treatment of severe cases 
and crusted scabies (Cook & Romanelli, 2003; Currie et al., 1995). Permethrin is the topical 
treatment of choice for scabies infections, due to safety concerns with lindane, benzyl benzoate 
requiring an application time of 24 hours (Elgart, 1996), and repeated applications of 
crotamiton required for effective treatment of infections (Taplin et al., 1990). Treating scabies 
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at a case by case level has proved to be ineffective at reducing the prevalence of scabies for the 
long term in endemic scabies areas. Thus, re-admission of the same patient for repeated scabies 
treatments is commonly seen at significant cost to individuals and the healthcare system 
(Whitehall et al., 2013). Mass administration of scabicides at a community wide level has 
shown to be more successful in working towards eradication of the disease (Taplin et al., 1991; 
Wong et al., 2001). Some programs have also shown that by treating scabies infections alone, 
secondary bacterial infections, which are commonly found in conjunction with scabies, are also 
reduced by approximately 50% (Andrews et al., 2009; Carapetis et al., 1997). 
 
1.5 Secondary bacterial infections 
Scabies-associated secondary bacterial infections are predominately caused by the 
opportunistic pathogens, Streptococcus pyogenes, otherwise known as Group A Streptococcus 
(GAS) and Staphylococcus aureus. Primary modes of entry for these pathogens is by disruption 
of the host epidermis from the burrowing action of the scabies mite or through scratching of 
the skin by the host, due to irritation during scabies infection. These conditions provide a portal 
of entry for the bacteria to bypass the epidermal barrier, which then may result in the 
development of “skin sores” – the most common form of which is pyoderma – or pus-forming 
skin disease, as shown in Figure 3.  
 
Figure 3. Presentation of scabies infection with secondary bacterial pyoderma.  
Image courtesy of Steer et al. (2009) (PLoS is an open-access journal and therefore no 
permission is required from the authors or the publishers) 
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In some remote Indigenous Australian communities, up to 70% of children will contract scabies 
and develop pyoderma before they reach 2 years of age (Clucas et al., 2008). Additionally, a 
recent study of children in five remote Aboriginal Australian communities in the Northern 
Territory, found that co-infection of scabies and skin sores occurs at 7 times the rate of skin 
sores alone (Kearns et al., 2013). GAS pyoderma is the most common secondary condition to 
scabies, the chronic form of which may lead to several debilitating and potentially fatal 
sequelae, including; post-streptococcal glomerulonephirits (PSGN), rheumatic fever (RF) and 
rheumatic heart disease (RHD) (Andrews et al., 2009).  
 
1.6 Rheumatic heart disease (RHD) 
RHD is a chronic complication of the autoimmune disease RF, which occurs as a result of 
untreated recurrent GAS infections in susceptible individuals, mainly children. RF commonly 
presents as inflammation of the joints (arthritis), nervous system (chorea), skin (erythema 
marginatum), or subcutaneous nodules (Chakravarty et al., 2014; Cunningham, 2008). Around 
60% of individuals that develop RF will go on to develop inflammation of the heart (carditis) 
or RHD, and up to 250,000 deaths occur as a result per year worldwide (Ralph & Carapetis, 
2013). The incidence of RF and RHD is considered rare in most developed countries, with a 
rate of 0.2 – 1.9 persons per 100,000 inhabitants, while in many developing countries the 
incidence may be greater than 50 per 100,000 children (Azevedo et al., 2012). Globally the 
highest rates RF and RHD are seen in the Indigenous populations of industrialised countries 
such as Australia and New Zealand. Previous reports of the diseases were up to 100 per 100,000 
children in New Zealand (Lennon, 2000) and over 350 per 100,000 children in remote regions 
of central and northern Australia (AIHW, 2004). RHD is characterised by molecular mimcry 
of epitopes shared between GAS and the cardiac tissue of the host. The primary modes of cross 
reactivity for RF and RHD are attributed to the GAS surface carbohydrate N-acetyl 
glucosamine, and the GAS or streptococcal M protein, which contains structural similarities to 
cardiac myosin, resulting in antibody production and destruction to host tissues (Guilherme & 
Kalil, 2010). The M protein of GAS is a surface bound virulence factor that interferes with host 
mediated phagocytosis via complement inhibition. The sequence of the M protein gene, emm, 
is widely used for GAS strain typing, a process commonly termed emm-typing (McMillan et 
al., 2013). Emm-typing can be used to classify GAS strains into 3 distinct groups based on 
tissue tropism, or emm-pattern and includes emm-pattern A-C strains (predominately found to 
infect the throat, causing pharyngitis), emm-pattern D strains (primarily attributed to skin 
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infections causing pyoderma) and emm-pattern E strains (equally associated both with 
pharyngeal infections and with pyoderma)  (Bessen et al., 1997). 
 
1.7 GAS pyoderma and RHD 
There is a long standing paradigm that RF and RHD are secondary to GAS infections of the 
throat with GAS emm-patterns types A – C or E only (Bisno et al., 1970; Kaplan et al., 1970; 
Wannamaker, 1973), while PSGN can be caused by GAS infections of the all emm-pattern 
types (Blyth et al., 2007; Nissenson et al., 1979; Rodriguez-Iturbe & Batsford, 2007). This 
finding has been observed in infected individuals from temperate climates, geographic 
locations in which most of the earlier studies were undertaken. However, in global tropical 
regions such as northern Australia, the Pacific Islands and Hawaii, where the rates of RF and 
RHD are the highest worldwide – paradoxically, GAS pharyngitis is rare while GAS  pyoderma 
is common (Bessen et al., 2000; Hanna & Heazlewood, 2005; McDonald et al., 2008). It has 
also been proposed that Group C and G streptococci, that are more commonly found in the 
throats of infected individuals in tropical communities, may play roles in the pathogenesis of 
RF (Haidan et al., 2000). Besides the group C and G streptococci potentially being 
rheumatogenic, it has been theorised that due to high rates of recombination between groups 
A, C and G streptococci (Sriprakash & Hartas, 1996), virulence determinants linked to RF may 
be exchanged between the throat GAS strains and the more common skin GAS strains (Towers 
et al., 2004). While the role of pyoderma in tropical settings is generally acknowledged (Kaplan 
& Bisno, 2006; McDonald et al., 2004), and epidemiological evidence about the link between 
scabies and pyoderma exists, very little is known about the tripartite interactions between host, 
mites and bacteria. 
 
1.8 Molecular research into the biology of the scabies mite   
The molecular biology of S. scabiei is a relatively young field of research. The scabies mite 
genome discovery project commenced in 2001 and lead to the construction of a cDNA library 
from the human scabies mite, S. scabiei var. hominis (Fischer et al., 2003). A series of scabies 
mite genes homologous to several groups of Dermatophagoides spp. house dust mite (HDM) 
allergens were identified within the scabies mite cDNA library, which has led to a research 
focus on pathogenesis and host-mite interactions. A key discovery was a multigene family of 
33 scabies mite protein homologs of group 3 HDM allergens, namely Der p 3 in D. 
pteronyssinus.  The group 3 HDM allergens are serine proteases, found in the fecal pellets and 
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digestive tracts of house dust mites, where they convey similar activities to the structurally-
related serine proteases; trypsin and chymotrypsin (Rawlings & Barrett, 1994). Interestingly, 
32 of the 33 scabies mite HDM homologs were found to contain mutations in the active site 
catalytic triad, and thus were predicted to be inactive (Holt et al., 2003). The 32 homologs have 
been named scabies mite inactivated protease paralogues - serine (SMIPP-S). Additiona lly, 
several serine protease inhibitors (serpins) were also identified in a cDNA library, dubbed the 
scabies mite serpins (SMSs). Serpins function by irreversibly inhibiting serine proteases in 
proteolytic pathways (Walton & Currie, 2007) and are found to control a variety of biologica l 
processes in wide range of organisms, such as animals, plants and microbes (Oh et al., 2013). 
In the context of human immunology, serpins play important roles in regulating several key 
innate immune responses, including clotting, inflammation and the complement cascade (Oh 
et al., 2013). Results of localisation studies using immunohistochemistry have shown that the 
scabies mite serpins and SMIPP-Ss are secreted in the mite gut and released into the mite faeces 
into the mite burrows within the host epidermis (Mika et al., 2012a; Willis et al., 2006). 
 
1.9 The host innate immune response to scabies 
As scabies mites burrow into the skin of the host, they ingest serum (Rapp et al., 2006) that 
contains several host defence mechanisms, including complement, a critical component of the 
innate immune response to invading pathogens. The proteins that make up the complement 
system comprise over 15% of the globular component of human plasma. Complement function 
is triggered following the activation of one or more of its three distinct pathways, namely the 
Classical, Lectin and Alternative pathways (Walport, 2001). Activation of the Classical 
pathway is triggered by the binding of the complement component 1 complex (C1 complex) to 
the Fc region of an antibody-antigen complex. This leads to a cascade of proteolytic reactions 
catalysed by C1r and C1s subunits of the C1 complex, which results in the cleavage of 
complement components C4 and C2 and the deposition of a central complement component, 
C4b2a, on the target cell surface. The Lectin pathway is activated by the soluble pattern 
recognition receptors (PRRs); mannose binding lectin (MBL), ficolins or collectins, which 
recognise a specific group of highly conserved molecules present on the surface of 
microorganisms, termed pathogen-associated molecular patterns (PAMPs). The activation of 
PRRs in turn activates MBL-associated serine proteases (MASPs), which are structurally and 
functionally similar to the C1 complex subunits, C1r and C1s in the Classical pathway, also 
resulting in the formation of C4b2a. The Alternative pathway is initiated by spontaneous 
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hydrolysis of complement component 3 (C3), with C3b binding to the target cell surface, which 
then recruits factor B. Factor B is next cleaved by factor D, resulting in the formation of C3bBb 
(Frank & Fries, 1991). Here, properdin plays a key role in the association of C3b and factor B 
and to stablise the formation of C3bBb on the cell surface (Hourcade, 2006). C3bBb and C4b2a 
are two forms of the enzyme C3-convertase, the key complement component in which all three 
pathways converge. C3-convertase cleaves C3 into C3a and C3b. C3a functions as an 
anaphylatoxin, while C3b acts as an opsonin, which binds to the pathogen surface, tagging the 
cell for phagocytosis. Under high local concentration of C3b, C3b can also complex with an 
existing C3-convertase, to form C5-convertases, which cleaves C5 into C5a and C5b. C5a is a 
major anaphylatoxin that recruits phagocytes such as neutrophils to the site of infection. C5b 
complexes with complement component 6 (C6) to form the C5b-6 complex, which binds to the 
target cell surface and catalyses the assembly of the membrane attack complex (MAC), by 
recruitment of complement components 7 to 9 (C7, C8 and C9), causing direct lysis of the 
target cell (Frank & Fries, 1991). An overview of the human complement cascade is shown in 
Figure 4. 
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Figure 4. An overview of the human complement cascade.                                       
Reproduced with permission from Swe, Reynolds and Fischer (2014). 
A previous study reported that activated complement components were absent in the gut of the 
scabies mite, despite the localisation of the activating components, C1q and MBL (Mika et al., 
2011). For the scabies mite to feed on host serum without the activation of host defences, it 
therefore requires the ability to disrupt the function of the complement system.  
 
1.10 Pathogen serpins and inactive proteases 
The human complement cascade is regulated by a series of serine proteases to prevent 
unwanted targeting of host cells by innate immune defences (Degn & Thiel, 2013). Many 
pathogens have evolved to possess a range of sophisticated mechanisms to overcome the host 
complement system, by mimicking or recruiting the host regulatory proteins to enable the 
pathogen to feed or establish an infection without the threat of the host immune response (Blom 
et al., 2009; Cavalcante et al., 2003; Kasper et al., 2001; Suchitra & Joshi, 2005). Parasitic 
arthropods that are closely related to S. scabiei, such as ticks, are also known to produce a 
variety of complement inhibitors (Daix et al., 2007; Nunn et al., 2005; Tyson et al., 2008). 
Interestingly, serpins have been identified in the saliva and midgut of some Ambyloma spp. and 
Rhiphicephalus spp. ticks (Chalaire et al., 2011; Mulenga et al., 2003). Similarly, serine 
protease homologs have also been identified in parasitic arthropods (Ross et al., 2003; Simser 
et al., 2004). Due to amino acid substitutions at one or more catalytic residue(s), these serine 
protease homologs are proteolytically inactive. While potential functions of inactiva ted 
proteases no longer includes proteolysis, many have been found to possess alternat ive 
functional sites, reported to facilitate peptide binding to most commonly regulate proteolytic 
processes (Pils & Schultz, 2004). 
 
1.11 Scabies mite complement inhibitors 
Two scabies mite complement inhibitors (SMIPP-S) molecules, namely D1 and I1, have been 
reported to bind to the initial components of the three complement pathways, C1q, MBL  and 
properdin, causing functional inhibition of these pathways (Bergstrom et al., 2009). The 
authors showed that the deposition of downstream complement factors C4b, C3b and MAC 
was reduced in a concentration dependent manner, with SMIPP-S I1 having the greatest 
inhibitory action. A more recent study has shown that the inhibition of the Lectin pathway 
requires 40 times less SMIPP I1 and D1 than the inhibition of the other complement pathways 
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(Reynolds et al., 2014), indicating that the Lectin pathway is most likely the biological target 
of these mite complement inhibitors. Another study on two scabies mite serpins, SMS B4 and 
SMS B3 showed that both serpins inhibit various stages of the complement cascade (Mika et 
al., 2012a). SMS B4 was found to inhibit and directly bind to the activating and amplifica t ion 
components of all three pathways – including C1q, MBL and properdin, C4, C3 and the C6 
and C8 subunits of the membrane attack complex. SMS B3 was found to bind to C4, C3 and 
C8, with the most significant inhibition occurring at the level of the membrane attack complex 
(Mika et al., 2012a). More recent research by Swe and Fischer (2014) identified that when 
human complement was challenged with S. aureus, SMS B4 significantly reduced C3b 
deposition and properdin deposition, had no effect on MBL deposition, and significantly 
increased the deposition of C1q. However, C4b deposition was also reduced, a component 
produced by the activation of the Classical or Lectin pathways only, suggesting that the 
downstream processes of these pathways are disrupted. To assess the potential effects of 
scabies mite complement inhibitors on the recovery of scabies associated bacterial pathogens 
under physiological conditions, bactericidal assays were previously conducted in vitro with 
GAS strain 2967, emm-type emm 1, isolated from a patient with PSGN in Townsville, 
Queensland. A significant increase in bacterial recovery was observed in the presence of the 
scabies mite complement inhibitors, with a 15-fold increase of SMIPP-S I1 treated samples, 
and a 5-fold increase of SMS B4 treated samples, in relation to no effect with the negative 
control samples - treated with Bovine Serum Albumin (BSA) (Mika et al., 2012b). This result 
displays a clear suppression of blood killing of S. pyogenes by SMIPP-S I1 and SMS B4, which 
may promote the establishment of secondary bacterial infections in scabies infected hosts. 
More recently it has been shown that SMS B4 increased the blood killing of a range of 
Staphylococcus aureus clinical isolates (Swe & Fischer, 2014).  In this study it was found that 
SMS B4 reduced opsonisation on the surface of S. aureus and inhibited the phagocytosis of S. 
aureus by human neutrophils in vitro (Swe & Fischer, 2014). It is proposed that this effect may 
be attributed to the reduced opsonisation and anaphylatoxin production in the presence of SMS 
B4, which results in reduced complement mediated phagocytosis of the pathogen. Due to the 
disruption of the host, micro-environment and microbe balance in scabies infested skin lesions, 
it is important to consider the role of the host skin microbiome in clinical outcomes. Recent 
research has highlighted that interactions between the host complement and resident flora of 
the skin have been found to play important roles in regulating innate immune responses to 
cutaneous infections (Chehoud et al., 2013; Oh et al., 2013). A schematic representation of the 
hypothesised pathogenesis of scabies and secondary bacterial infections is shown in Figure 5. 
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Figure 5. Schematic representation of scabies mite-host-bacteria microenvironment.  
Mite complement inhibitors SMIPP-S I1 and SMS B4 localisation (depicted in red) and 
subsequent colonisation of mite burrows by opportunistic bacterial pathogens (depicted in 
green). Reproduced with permission from Fischer et al. (2012) 
 
1.12 Skin damage, complement inhibition and the cutaneous microbiome 
The commensal bacteria of the skin reside in a variety of skin niches determined by the 
chemical and physical conditions of the skin.  This skin microbiome provides resistance to 
colonisation by opportunistic and pathogenic microorganisms, whereby the residentia l 
microflora directly kills or out-competes the intruding species for resources and space (Chiller 
et al., 2001). Disruptions or imbalances of the skin microflora ecosystem have been linked to 
a range of skin disorders and infections (Sanford & Gallo, 2013). A recent study investiga ted 
the dynamics of the skin microbiome following superficial injury to the epidermis (Zeeuwen 
et al., 2012). The microbiota composition of injured skin remained significantly disturbed, 
compared to the baseline uninjured skin, after the injured skin had healed completely, as 
confirmed by clinical and microscopic examination 14 days into the study. This suggests that 
mechanical disruption of the skin can produce considerable changes to the commensa l 
protective microbes, which may have implications for related infectious skin diseases such as 
scabies and pyoderma. Another study investigated the effect of complement inhibition on the 
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diversity of skin microflora and the innate immune response in a mouse model of human 
disease. Administering a peptide inhibitor to the C5a receptor (C5aR), resulted in reduced 
diversity and altered taxonomic composition of the skin microbiome over time, down 
regulation of pro-inflammatory gene expression and significant reduction in the infiltration of 
macrophages and lymphocytes into the epidermis (Chehoud et al., 2013). These findings 
suggest an interactive role between complement and the microbial ecosystem of the skin, which 
may have important implications for inflammatory and infectious skin disorders (Chehoud et 
al., 2013). Over a 21 week trial in a porcine model of the scabies infection, skin scrapings were 
collected for analysis of microbiome dynamics using 16S rDNA pyrosequencing. A significant 
alteration in the epidermal flora was observed, with a decrease in taxonomic diversity and the 
increase in pathogenic Staphylococcus spp. occurring at the onset of the scabies infection, and 
remaining beyond the treatment and recovery phases (Swe et al., 2014). These findings suggest 
that scabies infections causing local complement inhibition in the confined microenvironment 
of the epidermal mite burrows may alter the delicate balance of healthy skin microbiota and 
support the establishment of opportunistic pathogens. 
 
1.13 Significance 
In October 2013, scabies was formally recognised as a neglected tropical disease by the World 
Health Organisation (Steer, 2014). A contributing factor to this recognition can be attributed to 
a worldwide collaborative publication, highlighting the ubiquitous nature of scabies infections, 
and the largely ignored burden it places on many aspects of society (Engelman et al., 2013). A 
study conducted between 2005 and 2010, in a hospital located in Mt Isa, Queensland illustra tes 
the current social and economic burden in northern Australia. The study found that at least 10% 
of Indigenous paediatric medical admissions were due to pyoderma with presumed scabies 
infections (Whitehall et al., 2013). Significantly, the number of cases increased from 10 to 39 
from 2005 to 2010, with an estimated minimum cost of around $10,000 per case.  From the 
total 113 admissions for pyoderma and presumed scabies, skin swabs were screened from 79 
patients; 71% of which were found to grow S. pyogenes or GAS strains (Whitehall et al., 2013).  
There is a growing concern regarding the limited treatment options and emerging drug 
resistance of scabies mites (Mounsey et al., 2008; Mounsey et al., 2009). This creates an 
urgency to identify novel therapeutic targets; hence further investigation and characterisat ion 
of the scabies mite molecules that are critical for survival, such as the complement inhibito rs, 
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SMIPP-S I1 and SMS B4, may provide results indicating the potential of these molecules as 
therapeutic targets.  
This project builds upon the earlier research with SMIPP-S I1 and SMS B4 by investiga t ing 
the effects on bacterial growth of these scabies mite proteins on a range of GAS clinica l 
isolates, some of which were isolated from scabies patients. Past research has been conducted 
on a single GAS isolate only (Mika et al., 2012a). Additionally, my project aims to investiga te 
complement deposition on whole bacterial cells; while earlier studies used artificial substrates 
(Bergstrom et al., 2009; Reynolds et al., 2014). Finally, I aim to investigate the potential of 
SMIPP-S I1 and SMS B4 to interfere with the phagocytosis of S. pyogenes by neutrophils. 
 
1.14 Aims and Hypothesis 
1.14.1 Hypothesis 
Scabies infections cause local complement inhibition in the epidermal burrows of their hosts, 
promoting the establishment of opportunistic pathogens and the risk of severe secondary 
bacterial diseases. A schematic representation of this proposed process by Mika et al., (2012b) 
is shown in Figure 6. 
 
 
Figure 6. Proposed relationship between scabies infections and group A streptococcal 
disease. Reproduced with permission from Mika, et. al., (2012b). 
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1.14.2 Aims 
This project aims to address the mechanism of action of the scabies mite complement 
inhibitors, SMIPP-S I1 and SMS B4, in promoting the growth of GAS isolates from the 3 
different emm-pattern groups of GAS i.e. (1) A – C (throat specialists), (2) D (skin specialists) 
and (3) E (generalists). The project is also designed to investigate the effects of these mite 
complement inhibitors on the host complement component deposition on the bacterial surface 
and subsequent phagocytosis by neutrophils.  
 
1.15 Experimental approach 
The approach utilised in this study was in vitro assays that aimed to closely represent the in 
vivo conditions of scabies and secondary bacterial infections. There are three primary methods 
that were employed and these included: 
1. Scabies mite complement inhibitors SMIPPS- I1 and SMS B4 were produced using 
Pichia pastoris and Esherichia coli recombinant protein systems. 
 
2. Bactericidal assays were performed with SMIPP-S I1 and SMS B4 to assess whether 
the complement inhibitor promoted the growth of all GAS strains, or specific GAS 
serotypes. 
 
3. Immunoassays were performed with SMIPP-S I1 and SMS B4 to determine the 
effect(s) on (a) the deposition of various complement components on GAS, assayed 
using ELISA and (b) phagocytosis by neutrophils, as measured by flow cytometry.  
 
Ethical clearance for this project was granted by QIMR Berghofer Medical Research Institute 
and the Queensland University of Technology, under ethics approval # 1400000235. 
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Chapter 2: Materials and 
Methods 
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2.1  Production of recombinant scabies mite proteins 
 
2.1.1  Expression of recombinant scabies mite inactivated protease paralogue – serine 
(SMIPP-S) I1 in Pichia pastoris 
 
Unless otherwise stated; all expression procedures were carried out in a biosafety cabinet of 
the type specified for PC2 containment. All equipment, the autoclaved culture bottles/lids and 
gloves were sterilised with 80% ethanol. The Pichia pastoris strain KM71H (Life 
Technologies, Australia) was used for recombinant SMIPP-S I1 expression. These clones were 
generated and stored at -80oC prior to this project, using the pPICZ alpha A vector (Invitrogen, 
USA), that includes an alcohol oxidase (AOX) promoter and secretion signal, for purifica t ion 
of the recombinant protein from the culture supernatant. The expression and purifica t ion 
protocol employed here for SMIPP-S I1 was previously developed by Bergstrom et al. (2009).  
 
A starter culture was produced by adding 40 µl of a glycerol stock of Pichia pastoris SMIPP-
S I1 clone to 400 ml of complete Buffered Glycerol Complex Yeast (BMGY) media 
(Appendix). This was then divided between two baffled culture flasks and incubated at 28oC, 
220 rpm for approximately 60 hrs. After this time a further 12 L of BMGY complete media 
was prepared in 1 L Schott bottles. To each bottle, 25 ml of the P. pastoris starter culture was 
added and each bottle was then divided evenly between 3 baffled culture flasks and incubated 
at 29oC, 230 rpm for 24 hours. This process was repeated for a total of 36 culture flasks. 
Approximately 200 ml of starter culture remained, which was used to prepare glycerol stocks 
for future starter culture batches, as follows: in 1 ml cryovials (Greiner Bio-One, Australia), 
400 µl volumes of starter culture was added to 400 µl of 50% glycerol and stored at -80oC.  
 
Each 24 hour culture was added to 500 ml centrifuge tubes, and centrifuged at 2900 rpm (rotor 
JA-10, Beckman Coulter, USA), at RT (20oC) for 8 min. The supernatant was discarded, 
retaining cell pellets - with the cell pellets from two culture flasks harvested together in each 
centrifuge tube. 400 ml of complete induction media was split between 3 centrifuge tubes and 
the harvested cell pellets re-suspended. The 3 centrifuge tube cultures was then divided 
between 2 baffled culture flasks (each with 200 ml of culture) and incubated at 28oC, 220 rpm 
for 72 hrs. This process was repeated for a total of 12 culture flasks.  
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At each 24 hr interval, 1.25 ml of 100% high grade methanol (Sigma, USA) was added to each 
flask to induce expression of recombinant SMIPP-S I1. The contents of the 12 culture flasks 
were divided between 6 x 500 ml centrifuge tubes, and centrifuged at 8500 rpm (rotor JA-10, 
Beckman Coulter, USA), at 4oC for 30 min; The culture supernatant (containing the 
recombinant SMIPP-S I1) was retained in sterile 1L Schott bottles, and stored at 4oC for 
purification the following day (or at -80oC if purification was scheduled for a later time). 
Approximately 2.4 L of supernatant was produced per batch. 
 
2.1.2  Purification of SMIPP-S I1 from P. pastoris 
 
The P. pastoris supernatant containing SMIPP-S I1 was filtered with 0.45µm filter and 
concentrated to approximately 200 ml using a Ultrasette Lab Tangential Flow Device (10 kDa 
cut off, PALL Life Sciences, USA) with Masterflex console drive (Cole-Palmer, USA) at RT.  
Precipitation of unwanted proteins was performed by gradually adding ammonium sulphate to 
a final concentration of 1.5 M. The pH was then adjusted to pH 5.0, and the solution was 
centrifuged at 11,250 rpm (rotor JLA 10.5, Beckman Coulter, USA) at 4°C for 30 mins.  
 
The resulting supernatant was retained and again passed through a 0.45µm filter in preparation 
for hydrophobic interaction chromatography. This was performed by: loading the filtrate onto 
a 5 ml HiTrap phenyl-sepharose column (GE Healthcare, USA) pre-equilibrated with 50 ml of 
SMIPP equilibration buffer (Appendix). Any unbound material was removed by a wash step 
with an additional 50 ml SMIPP equilibration buffer. Protein was eluted by stepwise gradient 
with 50 ml of SMIPP elution buffers 1, 2 and 3 (Appendix).  
 
Eluted fractions were dialysed against SMIPP dialysis buffer (Appendix) as follows: 33 mm 
cellulose dialysis tubing (Sigma, USA) was cut to 25 cm strips and pre-soaked in sterile water. 
To fill the tubing - one end was tied off, each elution was added to a separate dialysis bag, with 
the unsealed end tied tightly and a labelled microfuge tube attached to the knotted end of the 
tubing. The microfuge tube was inserted into a flotation device and the tubing was placed into 
a 5 L volume of SMIPP dialysis buffer, with constant stirring by a magnetic stirrer bar at 4oC 
for 48 hours. SMIPP dialysis buffer was changed twice each day. To determine which dialysed 
elution sample contained SMIPP-S I1, a 1 ml sample was removed from the dialysis tubing 
and was analysed by SDS-PAGE under reducing conditions followed by Silver staining 
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(Materials and Methods section 2.1.5). Recombinant SMIPP-S I1 was identified by 
visualisation of 23 kDa protein band.  
 
Fractions containing recombinant SMIPP-S I1 were pooled and loaded onto a 5 ml HiTrap SP-
Sepharose FF column (GE Healthcare, USA), pre-equilibrated with SMIPP binding buffer 
(Appendix). Any unbound protein was removed by a wash step with an additional 50 ml of 
SMIPP binding buffer, followed by elution of protein over a linear gradient of 0-0.4 M NaCl 
over 30 ml (15 ml binding buffer + 15 ml elution buffer slowly mixed using a dual chamber 
100 ml gradient mixer (Biophoretics, USA)); collecting 10 x 3 ml fractions.  
 
Fractions containing recombinant SMIPP-S I1 were identified by SDS-PAGE under reducing 
conditions with protein detection by Coomassie staining (Materials and Methods section 2.1.5). 
This was then concentrated further to 500 µl volumes using Amicon Ultra 15 ml centrifuga l 
columns (10 kDa molecular weight cut off (MWCO), Millipore, USA) by centrifugation at 
4˚C, 3,800 xg (rotor SX4750, Beckman Coulter, USA) for 30 min, with the flow through 
retained on ice. Bradford protein assay (Materials and Methods section 2.1.6) and SDS-PAGE 
analysis was performed on all collected elutions to estimate concentration and purity of 
recombinant SMS B4 protein. 100 µg aliquots were stored at -80˚C until use. SMIPP-S I1 
aliquots were buffer exchanged into Gelatin Veronal Buffer (GVB) (Appendix) before use in 
bactericidal and immunoassays using Amicon Ultra 0.5 ml centrifugal columns (3 kDa 
MWCO, Millipore, USA) per manufacturer’s instructions. 
 
 
2.1.3  Expression of recombinant scabies mite serpin (SMS) B4 in Escherichia coli 
 
Recombinant expression of SMS B4, was performed with SMS B4 plasmid (pB4) previous ly 
constructed before this project. The pB4 construct consists of the pQE9 plasmid vector 
(Qiagen, USA) containing the SMS B4 cDNA sequence (Mika et al., 2012a). The pQE9 
plasmid vector features an ampicillin resistance gene for selection, a partial lac operon for 
induction with lactose or Isopropyl β-D-1-thiogalactopyranoside (IPTG) and a hexa-histid ine 
tag for affinity chromatography purification. The expression and purification protocol 
performed here was previously established by Mika et al. (2012a) 
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To produce transformants of E. coli for SMS B4 expression, pB4 was transformed into calcium 
competent E. coli BL21 (DE3) cells (Qiagen, USA) by heat shock, as follows: a 100 µl aliquot 
of calcium competent E. coli BL21 was thawed on ice, to which a 1 µl aliquot of pB4 was 
added. The tube was left on ice for 30 min, before adding to a 42˚C water bath for 90 sec. Cells 
were immediately placed on ice for 2 minutes, before 250 µl of Super Optimal broth with 
Catabolite repression (S.O.C) medium (Invitrogen, USA) was added and the cells were allowed 
to recover by shaking at 37˚C, 220 rpm for 1 hr. 50 µl of the cell suspension was plated onto 
lysogeny broth agar (LBA) + 100 µg/ml ampicillin (Appendix) along with 100 µl of 1/10 and 
1/100 dilutions in lysogeny broth (LB) (Appendix). Agar plates were incubated at 37˚C 
overnight, under aerobic conditions, with plates carrying transformants stored at 4˚C.  
 
For expression of SMS B4, a 500 ml Schott bottle containing 100 ml of LB supplemented with 
100 µg/ml ampicillin (Sigma, USA), was inoculated with an individual pB4 E. coli BL21 
transformant. This was incubated at 37˚C, 220 rpm overnight, under aerobic conditions. 
Overnight culture was used to inoculate 3 x 800 ml of 2YT media (Appendix) supplemented 
with 100 µg/ml ampicillin at a starting optical density at 600 nm (OD600) of 0.05. The required 
inoculum was determined by measuring the overnight OD600 of the culture by 
spectrophotometer and performing the calculation using equation 1.  
 
Each 800 ml bottle of culture was evenly divided into 4 x 200 ml volumes in 1L Schott bottles. 
This was repeated for a total of 12 culture bottles. Each bottle was then incubated at 37˚C, 220 
rpm under aerobic conditions for approximately 3 hrs, when the OD600 reached 0.5-0.7. To 
induce SMS B4 expression, 100 µl of 1 M IPTG stock (Appendix) was added to each 200 ml 
culture, and the bottles were further incubated at 37˚C, 220 rpm for 4 hrs. To harvest the E. coli 
BL21 cells for purification of SMS B4, 2 x 200 ml culture flasks were added to 500 ml 
centrifuge tubes for centrifugation at 6000 rpm (rotor JA10, Beckman Coulter, USA) for 20 
min at 4˚C. The resulting supernatant was discarded, and the retained cell pellets resuspended 
in 6 ml serpin buffer each (6 cell pellets in total). Cell pellets were transferred to 50 ml 
centrifuge tubes (Greiner Bio-one, Australia) and stored at -80˚C until purification of 
recombinant SMS B4 was undertaken.  
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2.1.4  Purification of recombinant SMS B4 from E. coli 
 
Recombinant SMS B4 E. coli cell pellets were thawed at RT in a beaker containing water, 
when almost completely thawed, all tubes were then kept on ice between subsequent steps. The 
6 tubes were pooled together into 2 x 18 ml volumes, to which 480 µl of 50 mM PMSF (1 mM 
final, Life Technologies, Australia) was added to each and mixed well with the cell pellet 
suspension in a fume hood. 1200 µl of 10 mg/ml lysozyme (0.5 mg/ml final, Life Technologies, 
Australia) was then added, along with 48µl DNAse (0.02 mg/ml final, Life Technologies, 
Australia) and the cell pellet suspension tubes were incubated at RT on rollers for 1 hr. The 
cell suspensions were homogenised with a Potter-Elvehjem homogeniser (Sigma, USA) until 
the cell suspension took on an even consistency. A Sonifer 250 sonicator (Branson, USA) was 
then used to lyse any remaining intact cells (40% amplitude, output control setting of 3) with 
2 cycles of 90 sec with 10 sec rest time between intervals.  
 
To isolate the SMS B4 inclusion bodies from the cell pellet lysate, each cell suspension was 
centrifuged at 12,000 xg for 20 min at 4˚C (rotor JA-17, Beckman Coulter, USA), the 
supernatant was discarded and the pellets resuspended in 15 ml of Serpin + Triton-X100 buffer 
(Appendix) pre chilled on ice using a vortex mixer and the Potter-Elvehjem homogeniser. This 
was repeated 5 times, until the inclusion body pellets became chalky and dense. To solubilis e 
the inclusion bodies 8 ml solubilisation buffer (Appendix) was added to each tube, followed 
by incubation at 4˚C on a roller for 1 hr.  
 
During this time, the Nickel–Nitrilotriacetic acid affinity resin (Ni-NTA) was prepared as 
follows: 2.5 ml of Ni-NTA matrix suspension (Qiagen, USA), was added to four empty 0.8 x 
4 cm PolyPrep Chromatography columns (BioRad, USA). The resin was allowed to settle and 
the ethanol storage buffer to flow through column, while ensuring liquid phase remained above 
resin at all times. The column was washed with 5 x 5 ml volumes of purified water, followed 
by 2 x 5 ml of cold binding buffer (Appendix) to activate the resin. A cap was placed on the 
column to stop the buffer flow and to facilitate binding of the His-tagged serpin to the Ni-NTA 
beads. A 4ml aliquot of the solubilised recombinant SMS B4 protein fractions were added to 
each column. A clear plastic cap was placed on top of each column and sealed tightly with 
parafilm. Each column was placed into empty 50 ml tubes, and incubated overnight at 4°C with 
end over end mixing on a rotisserie wheel.  
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On the following day Ni-NTA immobilized metal affinity chromatography was performed. 
Firstly, the SMS B4 bound Ni-NTA resins were allowed to settle and the flow through was 
collected. To remove any unbound material from the Ni-NTA columns, 2 x 5 ml of serpin wash 
buffer (Appendix) was added, collecting separate 5 ml elutions for each wash. To elute SMS 
B4, 2 x 3ml of serpin elution buffer (Appendix) was added, collecting separate 3 ml elutions.  
To determine which fraction(s) contained SMS B4, SDS-PAGE analysis was performed on all 
collected eluates, with the identification of SMS B4 by visualisation of 54 kDa protein band.  
Elutions 1 and 2 were generally found to contain SMS B4 and these solutions were pooled into 
2 x 12 ml volumes (each with 2 x elution 1 and elution 2 solutions). To refold the denatured 
SMS B4, the 2 x 12 ml eluates were dripped into 2 x 4 L of refolding buffer (Appendix) at 4˚C 
overnight at a rate of 1 drop per minute, with continuous gentle stirring.  
 
The resulting solutions were then concentrated to a final combined volume of 100ml using an 
10 kDa cut off Ultrasette Lab Tangential Flow Device (PALL Life Sciences, USA) with 
Masterflex console drive (Cole-Palmer, USA) at RT. The protein concentrate solution was 
further concentrated to 500 µl volumes using Amicon Ultra 15 ml centrifugal columns (10 kDa 
MWCO, Millipore, USA) by centrifugation at 4˚C, 3,800 xg (rotor SX4750, Beckman Coulter, 
USA) for 30 min, with the flow through retained on ice.  
 
Bradford protein assay and SDS-PAGE analysis was performed on all collected elutions to 
estimate concentration and purity of recombinant SMS B4 protein. Aliquots of 25 µg were 
stored at -80˚C until use. SMS B4 aliquots were buffer exchanged into GVB before use in 
bactericidal and immunoassays using Zeba Spin Desalting Columns, 0.5 mL (7 kDa MWCO, 
Thermo Scientific, USA) per manufacturer’s instructions. 
 
 
2.1.5  Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)   
 
Recombinant mite proteins were analysed by SDS-PAGE separation under reducing 
conditions. Polyacrylamide gels were prepared per the manufacturer instructions (BioRad, 
USA), at 10% polyacrylamide. A volume of 12 µl from each protein sample was mixed with 3 
µl 4X Laemmlis sample buffer (Appendix) and heated for 5 min at 90˚C before loading. A 
PageRuler protein ladder (Life Technologies, Australia) was included as a molecular weight 
standard. Gel electrophoresis was performed at 200 V for 45 min at 25 mAmps per gel, in 1X 
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SDS running buffer (Appendix). Gels were then stained with Coomassie Blue or silver to 
visualise protein bands.  
 
Silver Staining 
Following electrophoresis, polyacrylamide gels were fixed for 20 min in Silver stain fixing 
solution (Appendix) followed by 3 x 10 min washes in deionised water (dH2O). Gels were then 
submerged in Silver stain solution (Appendix) for 5-20 min, until protein bands were visib le. 
After this time, the silver stain solution was removed and mixed with 1 M NaCl in dH2O 
(Chem-supply, Australia) to precipitate excess silver before discarding. Silver stain stop 
solution (Appendix) was added to the protein gel for 15 min to stop the staining reaction, 
followed by rinsing and soaking in dH2O for 15 minutes, 3 times. All soaking steps were 
performed at RT with gentle agitation. 
 
Coomassive Blue Staining 
Following electrophoresis, polyacrylamide gels were soaked in Coomassie Blue stain solution 
(Appendix) for 10 min, followed by several volumes of Coomassie destain solutio n (Appendix) 
with a paper towel wick to absorb excess Coomassie, until only stained protein bands were 
visible. All soaking steps were performed at RT with gentle agitation. 
 
2.1.6  Bradford protein estimation  
 
During expression, purification and following buffer exchange, the concentration of 
recombinant scabies mite proteins was estimated using the Bradford Method (Bradford, 1976). 
A standard curve of 0-10 mg/ml of Bovine Serum Albumin (BSA) diluted in 0.9% NaCl was 
set up in a flat bottom 96-well microtitre plate, from which the concentration of protein 
preparations could be determined. The Bradford Assay reagent (BioRad, USA) was added to 
each sample and incubated for 15 min at RT. The BSA standard curve absorbance was 
measured at 595 nm with a POLARstar OPTIMA multi-detection plate reader (BMG Labtech, 
Germany) from which the concentration of the scabies mite protein preparation was calculated 
by interpolation with the BSA standard curve using POLARstar OPTIMA software version 
1.3.2 (BMG Labtech, Germany).  
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2.2  Preparation of Human blood products and bacterial strains 
 
2.2.1 Collection of human blood products for assays 
 
Whole human blood samples for bactericidal assays and neutrophil isolations were prepared 
from blood donated by healthy volunteers. Informed consent was obtained and ethics for this 
project was approved for the collection of human blood by the QIMR Berghofer Human 
Research Ethics Committee, Brisbane, reference number P443. All normal human serum 
collected for complement deposition assays were collected, pooled and de-identified by 
labelling tubes with collection date only. 200 µl and 500 µl aliquots were stored at -80oC until 
use unless otherwise stated.  
 
2.2.2  Glycerol collection of Group A Streptococcus (GAS) strains 
 
Group A Streptococcus (GAS) strains investigated in this study were a generous gift from 
Professor Sri Sriprakash at the Bacterial Pathogenesis Laboratory, QIMR Berghofer Medical 
Research Institute, Brisbane. The details of each isolate is shown in table 1. 
 
Table 1. Characteristics of Group A Streptococcus (GAS) strains examined in this study. 
GAS Strain Emm type Emm pattern Collection site 
Additional 
information 
5448 emm 1 A-C Throat  
PRS8 emm12 A-C Throat  
88-30 emm 97 D Skin 
Isolated from a scabies 
skin lesion of a child in 
Darwin* 
PRS30 emm 83 D Skin  
PRS55 emm 9 E Throat  
PRS15 emm 48 E Throat  
*as recorded by CDC (2014). 
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Each strain was grown in 5 ml Todd Hewitt Broth (THB) (Appendix) overnight at 37°C  under 
aerobic conditions with 5% CO2 from glycerol stock. The following day 500 µl of this was sub 
inoculated into 5 ml fresh THB (Appendix) and incubated at 37°C and 5% CO2 for a further 3 
hrs to reach mid log growth, after which time 400ul of culture was added to 400ul of 50% 
glycerol and stored at -80°C in 4 x 1ml cryovials (Greiner Bio-One, Australia). When preparing 
plates for assays, a 10 µl loop inoculum was taken from the glycerol stocks and streak plated 
onto Horse Blood Agar (HBA) (Appendix) and incubated overnight at 37°C under aerobic 
conditions with 5% CO2. Plates were stored at 4°C for up to 4 weeks. 
 
2.2.3  Growth curves for CFU estimation 
 
All GAS strains in Table 1 were grown in 5 ml THB overnight at 37°C under aerobic conditions 
with 5% CO2. The following day, an inoculum from the overnight cultures was each added to 
fresh tubes of 15 ml THB, at an OD600 of 0.5. The volume of inoculum was calculated with 
equation 1. All strains were then incubated at 37°C under aerobic conditions with 5% CO2 over 
18 hours, with hourly OD600 reading measured by spectrophotometer between 2 – 8 hours of 
growth. At each time point, serial dilutions from 10-3 – 10-5 of each culture were plated onto 
HBA (Appendix). The resulting growth (Appendix) was used to estimate cfu/ml of S. pyogenes 
isolates from corresponding OD600 values. 
 
2.3  Bactericidal assays 
 
2.3.1  Assay with multiple GAS clinical isolates 
 
Cultures of S. pyogenes strains were incubated overnight at 37°C, under aerobic conditions 
with 5% CO2 in 5 ml volumes of THB. The overnight OD600 of the cultures was measured by 
spectrophotometer, and aliquots of each individual culture were sub-inoculated into fresh 15 
ml volumes of THB to an OD600 of 0.05. These were then incubated for 3 hours until mid- log 
phase growth was reached. During this time, 15 ml of human blood was collected from a 
consenting healthy donor into 2 x 10 ml hirudin double walled blood collection tubes (Verum 
Diagnostics, USA) to prevent coagulation. After an hour, 100 µl blood was added to microfuge 
tubes with 2 µM of SMIPP-S I1 or SMS B4 in Gelatin Veronal Buffer (GVB), a buffer used  
for complement assays. Bovine Serum Albumin (BSA) at 2 µM in GVB was used as a negative 
control and GVB buffer only was used to estimate baseline bactericidal activity. The treated 
blood was incubated at 37°C and shaken at 200 rpm, for 30 minutes.  
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During this time the mid-log S. pyogenes cultures were serially diluted in Phosphate Buffered 
Saline (PBS) (Life Technologies, Australia) to 4 x 103 cfu/ml and 12.5 µl of this bacterial 
challenge dose was then added to the blood sample tubes and incubated for 3 hours at 37°C 
under aerobic conditions with end over end mixing. The total reaction volume was 140 µl and 
each sample condition was performed in triplicate. 50 µl aliquots from each reaction were then 
spread-plated onto HBA (Appendix) in duplicate, incubated overnight at 37°C and the resulting 
colonies counted and compared between sample conditions. 
 
2.3.2  Mite protein concentration curve 
This set of experiments was performed per method 2.3.1, with the following changes: Healthy 
donor blood was challenged with mite complement inhibitors over a range of concentrations, 
from 0 to 4 µM of SMIPP-S I1 and 0 to 0.4 µM of SMS B4. In this instance the effect of 
varying mite complement inhibitor concentrations on the growth of GAS was assessed with 
strain 88-30 only. 
 
2.4  Enzyme linked immunosorbent assays (ELISA(s)) 
 
2.4.1  Coating of 96-well microtitre plates with S. pyogenes 88-30 for ELISA 
A culture of GAS 88-30 was incubated overnight at 37°C, under aerobic conditions with 5% 
CO2 in 5 ml THB. The overnight OD600 of the culture was measured by spectrophotometer, 
sub-inoculated into fresh 15 ml THB to an OD600 of 0.05 and then incubated for 3 hours to 
reach mid log-phase of growth. Cells were collected by centrifugation at 3800 xg, 10 min, 4˚C 
(rotor SX4750, Beckman Coulter, USA), the supernatant discarded and the cell pellet 
resuspended in 15 ml sterile PBS. To wash the cells thoroughly, this was repeated twice more. 
The washed cell pellet was then resuspended in 5 ml sterile PBS and the OD600 measured by 
spectrophotometer. The OD600 of the cell suspension was diluted to 0.3 in sterile PBS, as 
calculated by equation 1. This was then diluted 10-fold to a final OD600 of 0.03 in 10 ml sterile 
PBS per 96-well Immuno-Maxisorp microtiter plate (Nunc, USA), as calculated by equation 
1. To coat the wells, 100 µl of this cell suspension was added to each well and the plate was 
covered and incubated at 37°C for 1 hr. GAS coated plates were stored at 4°C until use (a 
maximum of 3 days before discarding). 
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2.4.2  Normal human serum and mite complement inhibitors 
 
ELISAs were performed to measure complement deposition on GAS 88-30, using techniques 
adapted from previous complement deposition assays performed in the laboratory using S. 
aureus and scabies mite serpins (Swe & Fischer, 2014).  The wells of pre-coated GAS 88-30 
plates were first washed with 200 µl PBS-Tween, and thereafter between each step of the assay. 
Next, each well was blocked with block buffer (Appendix) for 2 hrs at room temperature.  
Pooled human serum diluted to 10% in GVB, was incubated with 0 – 4 µM SMIPP-S I1, 0 – 
0.4 µM SMS B4 or equivalent BSA controls in a V-bottom 96-well plate for 30 mins at 37°C 
under aerobic conditions. Each treatment condition was performed in duplicate for a total 
reaction volume of 70 µl, comprised of 35 µl serum and 35 µl of test protein in GVB buffer. 
50 µl of these reactions were transferred to 96-well plates pre-coated with GAS 88-30 with 
incubation under aerobic conditions at 37°C for a further 30 mins.  
 
To detect bound complement factors 60 µl aliquots of primary antibodies against human 
complement proteins were added for 1 hour at room temperature. Next, 60 µl corresponding 
Horse Radish Peroxidase (HRP)-conjugated secondary antibodies were added to each well, and 
the plates were incubated at room temperature for a further 30 min – 1 hr. The supplier details, 
combinations and incubation times for antibodies to individually detect each complement 
factor is detailed in Table 2. 
Table 2. Antibodies used to detect complement deposition on the surface of GAS 88-30. 
Primary 
antibody 
Source 
Secondary 
antibody 
Source 
Incubation 
times 
Dilution in 
Block buffer 
Anti – C1q* Rabbit Anti-rabbit* Goat 1 hr / 1 hr 1:4000 
Anti – MBL^ Goat Anti-goat* Rabbit 1 hr / 1 hr 1:1000 
Anti – properdin^ Goat Anti-goat* Rabbit 1 hr / 1 hr 1:4000 
Anti – factor B^ Goat Anti-goat* Rabbit 1 hr / 1 hr 1:4000 
Anti – C4c* Rabbit Anti-rabbit* Goat 1 hr / 30 min 1:4000 
Anti – C3d* Rabbit Anti-rabbit* Goat 1 hr / 30 min 1:4000 
Supplier: *Dako, Denmark ^R&D systems, USA. 
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To quantitate antibody binding, 60 µl o-phenylenediamine (OPD) reagent (Dako, Denmark) 
containing 0.01% hydrogen peroxide (KPL International, India) was added, followed by 
incubation at room temperature until the serum + GVB buffer only positive control changed to 
yellow. To stop the reaction, 50 µl of a 0.5 M sulfuric acid (Sigma, USA) in dH2O solution was 
added and the resulting absorbance was measured at OD490 on a POLARstar Optima 
fluorescent microtiter plate reader (BMG Labtech, USA). The absorbance determined in the 
serum only samples were considered as 100% complement deposition. 
 
2.4.3  Complement deficient human serum 
 
This set of experiments was performed per method 2.4.2, with the following changes: 50 µl of 
normal human serum and commercially purchased human serum with defined complement 
deficiencies as detailed in table 3, were incubated on GAS 88-30 coated 96 well plates. The 
steps involving serum treatment with complement inhibitors SMIPP-S I1, SMS B4 or BSA 
were omitted in this instance. The absorbance determined in the normal human serum samples 
were considered as 100% complement deposition 
 
Table 3. – Functional information of normal human serum and complement deficient sera 
used in complement assays with S. pyogenes 88-30. 
Abbreviation Meaning 
Affected 
pathway 
Pathways still fully 
functional 
NHS Normal human serum None All 
ΔC1q* C1q deficient serum Classical Lectin and Alternative 
ΔMBL^ MBL deficient serum Lectin Classical and Alternative 
ΔFactor B* Factor B deficient serum Alternative Classical and Lectin 
Supplier: *Quidel, USA ^Statens Serum Institut, Denmark. 
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2.5  Investigation of mite protein effects on phagocytosis 
 
 
2.5.1  FITC labelling of GAS 
 
A culture of GAS 88-30 was incubated overnight at 37°C under aerobic conditions with 5% 
CO2 in 5 ml THB. The overnight OD600 of the culture was measured by spectrophotometer, 
sub-inoculated into fresh 15 ml THB to an OD600 of 0.05 and then incubated for 5 – 6 hours 
until the OD600  reached 0.8 - 1.0. Cells were pelleted by centrifugation at 3,200 rpm, 4°C for 
10 min (rotor SX4750, Beckman Coulter, USA), discarding the supernatant and resuspending 
the cell pellet in 15 ml carbonate buffer (Appendix). To wash the cells thoroughly, this was 
repeated twice more.  
 
The washed cell pellet was then resuspended in 3 ml sterile carbonate buffer and the OD600 
measured by spectrophotometer. The OD600 of the cell suspension was adjusted to 0.3 in 
carbonate buffer, as calculated by equation 1. To label GAS 88-30, the cell suspension was 
incubated at 37°C for 30 min with Fluorescein isothiocyanate (FITC) solution (Appendix) at a 
final concentration of 0.01% FITC v/v. FITC labelled GAS 88-30 cells were pelleted by 
centrifugation at 3,200 rpm, 4°C for 10 min (rotor SX4750, Beckman Coulter, USA) and 
washed with 15 ml carbonate buffer; this was repeated twice to remove excess FITC.  
 
A 1/10 and 1/100 dilution of this solution was examined under a GE Healthcare DeltaVis ion 
Deconvolution Microscope (GE Life Sciences, USA) to verify FITC labelling was successful 
and consistent. FITC labelled GAS were aliquotted into 100 µl volumes and frozen at -80°C in 
a dark environment until use. 
 
2.5.2  Isolation of neutrophils from human blood by gradient centrifugation 
 
Neutrophils were isolated from 40 ml of whole human blood, by gradient centrifugation using 
a Histopaque-1077 (density 1.077 g/ml, Sigma, USA)/Histopaque-1119 (density 1.119 g/ml, 
Sigma, USA) gradient. Human blood was collected from a single healthy consenting donor into 
5 x 10 ml hirudin double walled blood collection tubes (Verum Diagnostics, USA). An 
additional 10 ml of blood was collected from the same donor into a standard blood collection 
without anticoagulant (Becton Dickinson, USA) and was left for 30 min at RT to allow clotting, 
before being placed on ice for a further 30 min.  
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The heparinised blood was pooled into a 50 ml centrifuge tube and left at RT for 10 min to 
reach ambient temperature. To create a density gradient to isolate human neutrophils, 3 ml 
Histopaque-1119 was added into 6 x 15 ml tube; 3 ml Histopaque-1077 was then carefully 
layered on top of each tube; lastly 6 ml of the RT heparinised blood was slowly overlayed. To 
separate blood components across the gradient, the tubes were then centrifuged at 700 xg, 22°C 
for 30 min (rotor SX4750, Beckman Coulter, USA) with the centrifuge brake off.  
 
While the heparinised blood was in the centrifuge, the clotted blood was centrifuged at 3000 
xg, 10 min for 22°C; the clot removed and the remaining liquid transferred into a fresh 15 ml 
tube. This was again centrifuged at 3000 xg, 10 min for 22°C (rotor SX4750, Beckman Coulter, 
USA), with the serum layer transferred into a fresh 15 ml tube (Becton Dickinson, USA) and 
stored on ice until use.  
 
Following centrifugation, the top plasma layer and middle buffy layer of the heparinised blood 
and histopaque solution was added to a new 15 ml tube with a sterile pasteur pipette. To isolate 
the granulocyte phase (predominately consisting of neutrophils), the lower buffy coat between 
the Histopaque-1077 and Histopaque-1119 phases was transferred to a new tube. The process 
is depicted in Figure 7. 
 
 
Figure 7. Isolation of human neutrophils from whole blood using gradient centrifugation.  
Note the location of the granulocytes (mostly neutrophils). Image courtesy of Sigma-Aldr ich 
(2011). 
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Generally a yield of 6 to 8 ml of the granulocyte layer was obtained from approximately 36 ml 
of whole human blood. To wash the cells, PBS was added to make up a total volume of 12 ml 
and centrifuged at 200 xg, 22°C for 10 min. To lyse any red blood cells remaining, the 
granulocyte pellet was re-suspended in a hypotonic solution of 5 ml sterile dH20. This was 
mixed well by inversion for 28 sec exactly and 5 ml of 1.8% NaCl (Chem-supply, Australia) 
in dH20 solution was added to recover the cells. The neutrophil preparation was again 
centrifuged at 200 xg, 22°C for 10 min, with the supernatant decanted carefully and the cell 
pellet gently re-suspended in 12 ml of HBSS+HSA buffer (Appendix). The centrifugation step 
was repeated once more, and the cell pellet re-suspended in 3 ml of HBSS+HSA buffer. On 
average, the entire procedure required 3 hrs from time of blood collection. 
 
2.5.3  Immunomagnetic isolation of neutrophils from human blood 
 
Neutrophils were isolated from 4 ml of whole human blood, by immunomagnetic negative 
selection using an EasySep Direct Neutrophil Isolation Kit (Stem Cell Technologies, USA). 
This isolation technique works by the addition of two reagents to whole human blood; the  
EasySep Direct Isolation cocktail, which contains monoclonal antibodies that select for all 
unwanted blood cells; and EasySep Direct RapidSpheres, magnetic particles which conjugate 
with the antibodies.  The addition of the EasySep Direct Isolation cocktail and Rapidspheres to 
freshly collected human blood tube (with anticoagulant), will lead to the formation of antibody 
complexes with all undesired cell types; i.e. red blood cells, platelets and other white blood 
cells.  The reaction mixture is placed under the influence of a magnetic field, and the magnetic 
conjugated antigen-antibody complexes adhere to the side of the tube, leaving the desired cells 
in the supernatant untouched.  
 
To isolate human neutrophils, human blood was collected from a single healthy consenting 
donor into 1 x 10 ml hirudin double walled blood collection tubes (Verum Diagnostics). An 
additional 10 ml of blood was collected from the same donor into a standard blood collection 
tube without anticoagulant (Becton Dickinson, USA) and was left for 30 min at RT to allow 
clotting, before being placed on ice for a further 30 min. During this time the heparinised blood 
was left at RT for 10 min to reach ambient temperature. To isolate human neutrophils, 2 ml 
volumes of the heparinised donor blood was then added to 2 x 5 ml polystyrene round-bottom 
tubes (Corning Science). Added to each tube was 100 µl of EasySep Direct Neutrophil Isolation 
32 
 
cocktail (Stem Cell Technologies) and 100 µl of EasySep Direct RapidSpheres (Stem Cell 
Technologies). The reaction was mixed well by pipetting up and down and left at RT for 5 min.  
 
The volume of each tube was topped up to 4 ml and each tube was placed into an EasySep 
Magnet and incubated for a further 5 min at RT. After 5 min incubation the supernatant from 
each tube was gently poured into new tubes, ensuring the original tubes remained in the magnet. 
An aliquot containing 100 µl of EasySep Direct RapidSpheres was added and the reaction was 
left to incubate at RT for 5 min. Each tube was placed into an EasySep Magnet (Stem Cell 
Technologies, USA) and incubated for 5 min at RT. After 5 min incubation the supernatant 
from each tube was gently poured into new tubes and the process was repeated once more 
without the addition of EasySep Direct RapidSpheres.  
 
To wash the cells, PBS was added to make up a total volume of 12 ml and centrifuge at 200 
xg, 22°C for 10 min. This was repeated 3 times in total with the supernatant decanted carefully 
between each wash step. The cell pellet was gently re-suspended in 2 ml of HBSS+HSA buffer 
(Appendix) for cell counting by haemocytometer. On average, the entire procedure required 
approximately 90 minutes from time of blood collection. 
 
2.5.4  Enumeration of isolated neutrophils by haemocytometer 
 
The amount of isolated neutrophils was estimated using a haemocytometer (Hauser Scientific, 
USA). This was done by adding 10 µl of neutrophil suspension to 90 µl of Trypan Blue (Sigma, 
USA). 10 µl of the neutrophil-Trypan Blue preparation was loaded onto a haemocytometer and 
the total number of cells in each of the 25 squares visualised and counted under a Primover t 
light microscope (Zeiss, Germany). The concentration of neutrophils was determined (as 
cells/ml) using equation 2:  
𝑁𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = 𝑡𝑜𝑡𝑎𝑙 # 𝑐𝑒𝑙𝑙𝑠 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 × 104 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 
The neutrophil preparation was diluted to 1 x 107 cells/ml. To verify the purity of the neutrophil 
preparation, 20 µl of the neutrophil preparation was diluted in 300 µl PBS and analysed by a 
FACS Canto A (Becton Dickinson, USA) flow cytometer by an expected size (forward scatter 
– FSC) and cell granularity (side scatter – SSC) parameters for neutrophils. Neutrophil 
preparations of 70% purity or greater were considered ideal for the phagocytosis assay. 
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2.5.5  Antibody detection of CD66b to confirm isolation of peripheral human neutrophils  
 
A 20 µL aliquot of FITC conjugated mouse anti-human CD66b (Becton Dickinson, USA) was 
added to a 100 µL volume of isolated human neutrophils (containing approximately 106 cells) 
and left on ice for 20 min. Labelling buffer (Appendix) was added to a total volume of 1.5 ml 
and centrifuged at 200 xg, 22°C for 10 min, the supernatant was discarded and the cell pellet 
re-suspended in 1.5 ml PBS. This was repeated 3 times to thoroughly wash the cells, before re-
suspending in 500ul HBSS+HSA buffer (Appendix) for analysis of neutrophil purity with a 
FACS Canto A (Becton Dickinson, USA) flow cytometer. 
 
2.5.6 Phagocytosis assay 
 
Fifty µl aliquots of the 20% serum prepared in step 2.6.2 was incubated for 1 hr at 37°C with 
50 µl of various concentrations of recombinant SMS B4 in the wells of a round bottomed 96-
well micro titre plate (Nunc, USA). 20% serum + BSA in place of SMS B4 was used as a 
positive control and BSA + 20% serum heated for 30 min was used as a negative control. To 
initiate phagocytosis, 5 ml of FITC labelled GAS 88-30, was added to each well to achieve a 
bacteria to neutrophil ratio of 10:1. 
 
 The plate was then incubated at 37°C on a horizontal shaker at 200 rpm for 40 min, before the 
reaction was stopped by the addition of 50 ml of 4% ice cold paraformaldehyde solution into 
the wells. The plate was left on ice for a further 30 min, before being centrifuged at 1500 rpm, 
4°C for 3 min. The cell pellets were gently washed twice with 200 µl ice cold PBS, by re-
suspending the cell pellet and centrifuging each time at 1500 rpm, 4°C for 3 min. Neutrophils 
that remained adherent to the bottom of the microtitre plate wells were re-suspended in 200 µl 
PBS, and the uptake of FITC-GAS was measured utilising a FACS Canto A (Becton Dickinson, 
USA) Flow cytometer measuring the mean fluorescence intensity of neutrophils with FACS 
Diva v.8.0. 
 
2.6 Statistical analysis 
 
Statistical analysis of results and graphs were generated using the software package; GraphPad 
Prism version 6 (GraphPad Software Inc., USA). Statistical significance was determined by 
Two-way ANOVA and Sidak’s or Dunnetts’s multiple comparisons test. Values of p<0.05 
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were considered significant. BD FACSDiva version 8.0 (BD Biosciences, USA) and FlowJo 
version 10 (Tree Star, USA) was used to analyse flow cytometry data and to generate graphs. 
  
35 
 
Chapter 3: Results 
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The aim of this research project was to determine if mite complement inhibitors, known to be 
released into the human skin during scabies infection, promote the growth of S. pyogenes under 
physiological conditions. Two well characterised mite complement inhibitors were used in this 
study: 
 
(1)  Scabies Mite Inactivated Protease Paralogue (Serine) I1 (SMIPP-S I1);  and 
(2)   Scabies Mite Serpin B4 (SMS B4). 
 
The effect of these mite complement inhibitors on the recovery of three S. pyogenes serotypes, 
i.e. emm pattern types, was assessed. These included: 
 
(1) (pattern A – C) strains that predominantly cause throat infections;  
(2) (pattern D) strains that predominantly cause skin infections; 
(3) (pattern E) strains that are reported to cause both skin and throat infections. 
 
Representatives from three S. pyogenes emm-pattern types were first assessed. Subsequent 
experiments were focused on S. pyogenes (GAS) strain 88-30 (emm-pattern D), a clinical strain 
isolated from a scabies skin lesion in the Northern Territory. Gelatin Veronal Buffer (GVB) 
(Appendix) and/or Bovine Serum Albumin (BSA) (Appendix) were used as controls 
throughout as indicated. 
 
3.1   The effect of scabies mite complement inhibitors on the in vitro recovery of 
S. pyogenes clinical isolates in whole human blood 
 
Bactericidal assays were performed with fresh human blood collected from a healthy 
consenting donor per Materials and Methods section 2.2.1. The effect of scabies mite 
complement inhibitors SMIPP-S I1 and SMS B4 on the “recovery” of GAS strains was 
observed (Figure 8) that is; the ability of the bacteria to remain viable and proliferate, following 
complement challenge in whole human blood. The results shown in Figure 8 are for all GAS 
strains per Table 1, Materials and Methods section 2.2.2. The effect of SMIPP-S I1 and SMS 
B4 was also observed over a concentration range (Figure 9) with GAS 88-30 only. The results 
for both figures are from 3 independent experiments, with each treatment repeated 3 times and 
each treatment repeat spread plated on Horse Blood Agar (HBA) (Appendix) in duplicate. 
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No effect was observed on bacterial recovery in the BSA-treated and the GVB treated control 
samples (Figure 8); this is consistent for all S. pyogenes strains assayed. Samples treated with 
a mite complement inhibitor, SMIPP-S I1 or SMS B4, showed statistically significant increases 
in the recovery of all S. pyogenes clinical isolates, ranging from approximately 2.5 to 5 fold for 
SMIPP-S I1 and approximately 5.5 to 7.5 fold for SMS B4.  
 
 
Figure 8. Scabies mite complement inhibitors, inactivated protease paralogue, serine (SMIPP-S I1) 
and Serpin B4 (SMS B4) increase the recovery of S. pyogenes clinical isolates in whole human blood.                   
S. pyogenes clinical isolates were harvested from mid-log growth phase culture. 50 cfu of each strain was challenged 
with fresh healthy donor blood pre-treated with either 2 µM SMSB4, 2 µM SMIPP-S I1, or negative controls 2 µM 
Bovine Serum Albumin (BSA) and Gelatin Veronal Buffer (GVB) only. At 3 hours, triplicates of each treatment were 
plated in duplicate on horse blood agar, and incubated overnight at 37oC, 5% CO2/95% air. Resulting bacterial growth 
was enumerated as cfu/ml. Bacterial recovery was calculated as the fold change compared with GVB only treated control. 
Results are reported as means ± SEM from three independent experiments, with samples performed in duplicate for each 
assay. The statistical significance of variance between treatments was estimated by Two-way ANOVA and Dunnett’s 
multiple comparison test. *, p<0.05 **, p<0.01; ***, p<0.001; ****, p<0.0001, ns, not significant. 
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Figure 9. Scabies mite complement inhibitors SMIPP-S I1 (A) and SMS B4 (B) increase the 
recovery of GAS 88-30 in whole human blood in a concentration dependent manner.                                                                  
S. pyogenes 88-30 was harvested from mid-log growth phase culture. 50 cfu of S. pyogenes 88-30 was challenged 
with fresh healthy donor blood pre-treated with increasing concentrations of SMIPP-S I1 (A) or SMS B4 (B). 
Equivalent concentrations of Bovine Serum Albumin (BSA) were used as negative controls. At 3 hours, triplicates 
of each treatment were plated in duplicate on horse blood agar, and incubated overnight at 37oC, 5% CO2/95% air.  
Resulting bacterial growth was enumerated as cfu/ml. Bacterial recovery was calculated as the fold change 
compared with gelatin veronal buffer in place of protein (0 µM samples). Results are reported as means ± SEM 
from three independent experiments, with samples performed in duplicate for each assay . The statistical 
significance of variance between treatments was estimated by Two-way ANOVA and Sidak’s multiple comparison 
test. **, p<0.01; ****, p<0.0001. 
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The effect of mite complement inhibitors on the recovery of scabies associated S. pyogenes 88-
30 is reported here (Figure 9). These results demonstrate that as the increasing concentrations 
of (A) SMIPP-S I1 or (B) SMSB4 is added, the recovery of S. pyogenes 88-30 in whole human 
blood increases. Increasing the concentration of BSA in negative control samples caused no 
change in bacterial recovery. These results show that SMS B4 has an effect on the recovery of 
S. pyogenes 88-30 at lower concentrations than SMIPP-S I1. The concentrations of these mite 
complement inhibitors used in subsequent experiments; 1 – 4 µM of SMIPP-S I1 and 0.1 – 0.4 
µM of SMS B4 were determined based on these results. 
 
3.2   The effect of scabies mite complement inhibitors on the formation of the C3 
convertase and opsonisation on the surface of S. pyogenes 88-30 
 
One of the primary innate immune responses to facilitate blood killing of pathogens is 
complement mediated C3b opsonisation and subsequent phagocytosis. The cleavage of C3 by 
the C3 convertases (C4b2a of the Classical pathway (CP) and Lectin pathway (LP); C3bBb of 
the Alternative pathway (AP)) complexes directly deposited on the cellular surface of 
pathogens. The potential of the scabies mite complement inhibitors, SMIPP-S I1 and SMS B4 
to disrupt these processes was assessed by measuring the deposition of C4b and C3b on the 
surface of S. pyogenes 88-30.  To achieve this, Enzyme Linked Immunosorbent Assays 
(ELISAs) were performed using Normal Human Serum (NHS), freshly collected from a 
consenting healthy donor, and S. pyogenes strain 88-30, which was originally isolated from a 
scabies patient in the Northern Territory, Australia. The procedure employed here is detailed 
in Materials and Methods section 2.4.2 
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Figure 10. Classical and Lectin pathway C3 convertase formation on S. pyogenes 88-30 is reduced 
in the presence scabies mite complement inhibitors SMIPP-S I1 (A) and SMS B4 (B).                                      
S. pyogenes 88-30 was incubated at 37oC, 5% CO2 for 4 hours and then diluted in phosphate buffered saline to an 
OD600 of 0.3; approximately 2x10
7 cfu/ml. 100 µl aliquots were used to coat the wells of 96-well microtitre plates. 
5% Normal Human Serum (NHS) diluted in Gelatin Veronal Buffer (GVB), pre-treated with increasing 
concentrations of SMS B4 or Bovine Serum Albumin (BSA) (A) and SMIPP-S I1 or BSA (B), was added in 
duplicate. Heated NHS and GVB in place of serum were used as assay controls. Plates were incubated for 30 minutes, 
and the deposition of C4b was detected with primary human specific antibodies, followed by horse radish 
peroxidase-conjugated secondary antibodies, and the resulting colourmetric change of o-phenylenediamine 
measured at 490 nm. Absorbance of GVB in place of serum samples was subtracted as background. Results are 
shown as means ± SEM from three independent experiments, with samples performed in duplicate for each assay. 
The statistical significance of variance between treatments was estimated by Two-way ANOVA and Sidak’s multiple 
comparison test. ***, p<0.001; ****, p<0.0001, ns, not significant.  
 
B 
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Figure 11. Mite proteins SMIPP-S I1 (A) and SMS B4 (B) reduce the opsonisation of GAS 88-30                     
S. pyogenes 88-30 was incubated at 37oC, 5% CO2 for 4 hours and then diluted in phosphate buffered saline to an 
OD600 of 0.3; approximately 2x10
7 cfu/ml. 100 µl aliquots were used to coat the wells of 96-well microtitre plates. 5% 
Normal Human Serum (NHS), pre-treated with increasing concentrations of SMS B4 or BSA (A) and SMIPP-S I1 or 
BSA (B), was added in duplicate. Heated NHS and GVB in place of serum was used as assay controls. Plates were 
incubated for 30 minutes, and the deposition of C4b was detected with primary human specific antibodies, followed 
by horse radish peroxidase-conjugated secondary antibodies, and the resulting colourmetric change of o-
phenylenediamine was measured at 490 nm. Absorbance of GVB in place of serum samples was subtracted as 
background. Results are shown as means ± SEM from three independent experiments, with samples performed in 
duplicate for each assay. The statistical significance of variance between treatments was estimated by Two-way 
ANOVA and Sidak’s multiple comparison test. ***, p<0.001; ****, p<0.0001, ns, not significant. 
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It is demonstrated here (Figure 10) that mite complement inhibitors SMS B4 and SMIPP-S I1 
both cause a significant reduction in the deposition of C4b on GAS 88-30. A reduction of 
approximately 40% of C4b can be observed at 2 µM of SMIPP-S I1, compared with the 
equivalent BSA treated sample. As the concentration of SMIPP-S I1 increases beyond 2 µM, 
the response saturates.  SMS B4 decreases C4b deposition on GAS 88-30 in a concentration 
dependent manner, with a 50% reduction at 0.4 µM.  
The effect of SMIPP-S I1 and SMS B4 on the deposition of C3b on GAS 88-30 (Figure 11) is 
very similar to the effects seen on C4b deposition (Figure 10). 2 µM of SMIPP-S I1 caused a 
reduction in C3b deposition of approximately 65%. In comparison the same concentration of 
BSA had no effect, as the C3b deposition remained 100%, as seen in the samples where no 
protein was added. As the concentration of SMIPP-S I1 increases beyond 2 µM, this response 
saturated. SMS B4 decreased C3b deposition on GAS 88-30 in a concentration dependent 
manner; up to approximately 60% when 0.4 µM concentration of SMS B4 was tested. 
Remarkably this concentration is 5-fold less than the concentration that was required of 
SMIPP-S I1 to achieve a >60% reduction of C3b deposition. 
 
3.3   The activation of the human complement system to S. pyogenes 88-30 in the 
presence of scabies mite complement inhibitors 
 
Previous research has shown that the mite complement inhibitors SMIPP-S I1 and SMS B4 
both inhibit the activation and progression of all 3 complement pathways in humans (Bergstrom 
et al., 2009; Mika et al., 2012a). In these experiments each human complement pathway was 
individually activated using specific homogenous substrates. This study has aimed to extend 
this previous area of research, by investigating the activation of human complement to the 
heterogeneous composition of the bacterial cell surface; namely S. pyogenes 88-30. 
3.3.1 The impact of scabies mite complement inhibitors on the activation of the 
complement pathways in response to S. pyogenes 88-30 
The aim of these experiments was to determine which complement pathway(s) are important 
for innate defence against S. pyogenes 88-30, and whether SMIPP-S I1 and SMS B4 interfere 
with the deposition of the key initiating factors of the relevant complement cascades on the 
bacterial surface. The key initiating factors tested were C1q of the Classical pathway (CP); 
Mannose Binding Lectin (MBL) of the Lectin pathway (LP); and properdin of the Alternat ive 
pathway (AP). 
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3.3.1.1 The binding of complement pathway activation factors to S. pyogenes 88-30 
The potential activation of the Classical, Lectin and/or Alternative pathway by the presence of 
S. pyogenes 88-30 was investigated by measuring the binding of C1q, MBL and properdin to 
the bacterial surface. A concentration range from 0 to 30% of Normal Human Serum (NHS) 
was incubated with 96-well microtitre plates pre-coated with S. pyogenes 88-30 cells. The 
binding of each activating complement factor was detected with specific antibodies per 
Materials and Methods section 2.4.2. 
 
 
The data reported here (Figure 12) indicates that MBL binding was not detected on the surface 
of S. pyogenes 88-30 at any of the measured serum concentrations. Increased binding of C1q 
and properdin was detected on S. pyogenes 88-30 with increasing serum concentrations, from 
0 to 30% respectively. Based on these data 5% normal human serum was used in all subsequent 
assays. 
Figure 12. Binding of pattern recognition molecules for the activation of the Classical, Lectin and 
Alternative pathways of the human complement system on the surface of S. pyogenes 88-30.                                       
S. pyogenes 88-30 was incubated at 37oC, 5% CO2 / 95% air for 4 hours and then diluted in phosphate buffered saline to an 
OD600 of 0.3; approximately 2x10
7 cfu/ml. 100 µl aliquots were used to coat the wells of 96-well microtitre plates. 50 µl 
aliquots of Normal Human Serum (NHS) of increasing concentrations diluted in Gelatin Veronal Buffer (GVB) were then 
added in duplicate. Heated NHS and GVB in place of serum was used as assay controls. Plates were incubated for 1 hr at 
37oC in 100% air, and the deposition of C1q, mannose binding lectin (MBL) and Properdin was detected with primary 
human specific antibodies against C1q, MBL and Properdin respectively, followed by horse radish peroxidase-conjugat ed 
secondary antibodies. Quantification of antibody binding was achieved using o-phenylenediamine (OPD). The resulting 
colourmetric change of OPD was measured at 490 nm. Absorbance at 0% serum was considered as background. Results 
are shown as means ± SEM from three independent experiments with each sample performed in duplicate for each assay.  
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3.3.1.2 The effect of scabies mite complement inhibitors on the activation of the Classical 
and Alternative pathways of the human complement system to S. pyogenes 88-30  
 
 
B 
Figure 13. Scabies mite complement inhibitors, SMIPP-S I1 (A) and SMS B4 (B) increase surface 
binding of C1q on S. pyogenes 88-30  S. pyogenes 88-30 was incubated at 37oC, 5% CO2 / 95% air for 4 hours 
and then diluted in phosphate buffered saline to approximately 2x107 cfu/ml. 100 µl aliquots were used to coat 96-well 
microtitre plates. Plates were incubated with 5% Normal Human Serum (NHS), pre-treated with concentrations of 
SMS B4 (A) and SMIPP-S I1 (B) for 1 hr. Samples treated with Bovine Serum Albumin (BSA) was included as a 
negative control; Heated NHS and Gelatin Veronal Buffer (GVB) in place of serum were used as assay controls. The 
deposition of C1q was detected with primary human specific antibodies, followed by horse radish peroxidase-
conjugated secondary antibodies, and the resulting colourmetric change of o-phenylenediamine measured at 490 nm. 
Absorbance of GVB in place of serum samples was subtracted as background. Results are shown as means ± SEM 
from three independent experiments with each sample performed in duplicate for each assay. The statistical 
significance of variance between treatments was estimated by Two-way ANOVA and Sidak’s multiple comparison 
test. *, p<0.05; ***, p<0.001; ****, p<0.0001, ns, not significant. 
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Figure 14. Scabies mite complement inhibitors, SMIPP-S I1 (A) and SMS B4 (B) decrease surface 
binding of properdin on S. pyogenes 88-30  S. pyogenes 88-30 was incubated at 37oC, 5% CO2 / 95% air for 4 
hours and then diluted in phosphate buffered saline to approximately 2x107 cfu/ml. 100 µl aliquots were used to coat 
96-well microtitre plates. Plates were incubated with 5% Normal Human Serum (NHS), pre-treated with 
concentrations of SMS B4 (A) and SMIPP-S I1 (B) for 1 hr. Samples treated with Bovine Serum Albumin (BSA) was 
included as a negative control; Heated NHS and Gelatin Veronal Buffer (GVB) in place of serum were used as assay 
controls. The deposition of properdin was detected with primary human specific antibodies, followed by horse radish 
peroxidase-conjugated secondary antibodies, and the resulting colourmetric change of o-phenylenediamine measured 
at 490 nm. Absorbance of GVB in place of serum samples was subtracted as background. Results are shown as means 
± SEM from three independent experiments with each sample performed in duplicate for each assay. The statistical 
significance of variance between treatments was estimated by Two-way ANOVA and Sidak’s multiple comparison 
test. *, p<0.05; ***, p<0.001; ****, p<0.0001, ns, not significant. 
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The results presented here (Figure 13) demonstrate that at the highest concentration tested, 4 
µM, SMIPP-S I1 significantly increased the binding of C1q to S. pyogenes 88-30, by 
approximately 10% above the values that were measured for equivalent concentrations of BSA, 
which served as a negative control. A similar result was observed when the deposition of C1q 
was measured in the presence of 0.2 µM to 0.4 µM of SMS B4. The C1q deposition was 
significantly increased from 20 to 30% compared with the BSA controls. 
Properdin deposition was also found to be significantly reduced on the S. pyogenes cell surface 
when subjected to SMIPP-S I1 and SMS B4 treatment, in comparison to the equivalent BSA 
controls (Figure 14). A reduction in properdin deposition of 25 – 35% was evident in the 
presence of 1 – 4 µM SMIPP-S I1 respectively. The reduction in properdin deposition in SMS 
B4 treated samples was much stronger, and ranged from 30% to 45% in the presence of 0.1 
µM to 0.4 µM of SMS B4 respectively. 
 
3.4   Assessing the opsonisation of S. pyogenes 88-30 in human serum with 
known complement deficiencies 
 
The next set of experiments aimed to determine which complement pathway(s) is/are most 
crucial for the opsonisation of S. pyogenes. To perform this, commercially sourced serum 
deficient in key activating complement components unique for each pathway – C1q (Classical), 
MBL (Lectin) and Factor B (Alternative) was used, as listed in Table 3, Materials and Methods 
section 2.4.3. The serum was incubated on S. pyogenes 88-30 coated 96-well microtitre plates 
at a 5% concentration. The deposition of complement components on the surface of S. pyogenes 
88-30 was detected using specific antibodies per Materials and Methods section 2.4.3.  
3.4.1 The effect of complement deficiencies on the opsonisation of S. pyogenes  
Opsonisation of target cells by C3b is the central process common to all 3 complement 
pathways following activation. Therefore, C3b deposition was assessed to determine the effect 
of complement deficiencies on the opsonisation of S pyogenes. In this instance 96-well 
microtitire plates were coated with S. pyogenes 88-30 and assayed with each commercial serum 
compared against the activity of pooled Normal Human Serum (NHS). 
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The experimental findings reported here (Figure 15) indicate that MBL deficient serum caused 
the greatest reduction of C3b deposition on S. pyogenes, approximately 60% less than the 
equivalent concentration of NHS. C1q deficient serum caused a reduction of around 40%, while 
the change in C3b deposition by factor B deficient serum was not found to be statistica l ly 
different to the control, NHS.  
3.4.2 Supplementing with heated anti-sera containing antibodies against S. pyogenes – to 
reassess the opsonisation of S. pyogenes by normal and complement deficient sera 
It was observed that MBL deficiency leads to the greatest reduction in opsonisation of S. 
pyogenes (Figure 15). As a C1q deficiency also leads to a significant reduction in opsonisation, 
it was postulated that the level of antibodies to S. pyogenes in each serum may not be equal. 
Figure 15. The effect of complement deficiency on opsonisation of GAS 88-30                                           
S. pyogenes 88-30 was incubated at 37oC, 5% CO2 / 95% air for 4 hours and then diluted in phosphate buffered saline to 
approximately 2x107 cfu/ml. 100 µl aliquots were used to coat 96-well microtitre plates. Wells were then incubated with 
5% Normal Human Serum (NHS), and Human serum deficient (denoted as Δ) in C1q, mannose binding lectin (MBL), or 
Factor B. Heated NHS and Gelatin Veronal Buffer (GVB) in place of serum were used as assay controls. The deposition of 
C4b was detected with primary human specific antibodies, followed by horse radish peroxidase-conjugated secondary 
antibodies, and the resulting colourmetric change of o-phenylenediamine measured at 490 nm. Results are reported as means 
± SEM from three independent experiments with each sample performed in duplicate for each assay. Fluorescence of GVB 
in place of serum samples was subtracted as background for analysis. The statistical significance of variance between 
treatments was estimated by Two-way ANOVA and Dunnett’s multiple comparison test. *, p<0.05; ****, p<0.0001, ns, 
not significant  
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Therefore, the experiment was repeated and additional samples were supplemented with heat 
inactivated serum from a donor shown to have antibodies against S. pyogenes (Mika et al., 
2012b) (Figure 16). 
 
 
Figure 16. The effect of complement deficiency on the opsonisation of GAS 88-30 when supplemented 
with S. pyogenes anti-sera. S. pyogenes 88-30 was incubated at 37oC, 5% CO2 / 95% air for 4 hours and then diluted 
in phosphate buffered saline to approximately 2x107 cfu/ml. 100 µl aliquots were used to coat 96-well microtitre plates. 
Wells were then incubated with 5% Normal Human Serum (NHS), and Human serum deficient (denoted as Δ) in C1q, 
mannose binding lectin (MBL), or Factor B. Heated NHS and Gelatin Veronal Buffer (GVB) in place of serum were 
used as assay controls. The deposition of C3b was detected with primary human specific antibodies, followed by horse 
radish peroxidase-conjugated secondary antibodies, and the resulting colourmetric change of o-phenylenediamine 
measured at 490 nm. Results are reported as means ± SEM from three independent experiments with each sample 
performed in duplicate for each assay. Fluorescence of GVB in place of serum samples was subtracted as background 
for analysis. 
49 
 
In the presence of heated anti-sera against S. pyogenes, the GVB buffer control produced a 
negligible amount of absorbance signal for the antibody detection of C3b deposition. NHS and 
Factor B deficient serum samples showed between 100% and 80% C3b deposition and 
exhibited very little change after the addition of anti-sera. Notably, C3b deposition in both the 
MBL deficient and C1q deficient serum were restored to a similar level to NHS, when 
supplemented with the anti-sera. 
 
3.4.3 Binding of C1q and Factor B to S. pyogenes 88-30 from normal human serum and 
complement deficient sera 
The Classical pathway is known to be activated by C1q binding to antibody complexes. The 
next set of experiments aimed to assess the level of C1q in each serum, compared with Normal 
Human Serum standard (NHS) (Figure 17).  
 
Figure 17. C1q concentration in complement deficient sera – binding on S. pyogenes 88-30                         
S. pyogenes 88-30 was incubated at 37oC, 5% CO2 / 95% air for 4 hours and then diluted in phosphate buffered saline 
to approximately 2x107 cfu/ml. 100 µl aliquots were used to coat 96-well microtitre plates. Wells were then incubated 
with 5% Normal Human Serum (NHS), and Human serum deficient (denoted as Δ) in C1q, Mannose Binding Lectin 
(MBL), or Factor B. Heated NHS and Gelatin Veronal Buffer (GVB) in place of serum were used as assay controls. 
The deposition of C1q was detected with primary human specific antibodies, followed by horse radish peroxidase-
conjugated secondary antibodies, and the resulting colourmetric change of o-phenylenediamine measured at 490 nm. 
Results are reported as means ± SEM from three independent experiments with each sample performed in duplicate 
for each assay. Fluorescence of GVB in place of serum samples was subtracted as background for analysis.  
 
50 
 
Secondly, as a deficiency in factor B appears to have little effect on the opsonisation of S. 
pyogenes, the factor B levels of each serum were also assayed to determine the levels of 
Factor B present in each donor sera (Figure 18). 
 
 
The results presented here (Figure 18) reveal that C1q deficient serum had a negligible level of 
detectable C1q. The factor B deficient serum had a similar amount of C1q as the NHS standard. 
Interestingly, the MBL deficient serum appears to have approximately 60% more C1q than the 
NHS standard. Figure 18 shows that Factor B deficient serum had a low level of detectable 
factor B, in comparison to the NHS standard; however C1q deficient serum had a similar 
amount of factor B to the NHS standard. The MBL deficient serum assay indicates 
approximately 30% less factor B was present in the MBL deficient serum, compared to the 
NHS standard.  
Figure 18. Factor B concentration in complement deficient sera - binding on S. pyogenes 88-30                                       
S. pyogenes 88-30 was incubated at 37oC, 5% CO2 / 95% air for 4 hours and then diluted in phosphate buffered saline 
to approximately 2x107 cfu/ml. 100 µl aliquots were used to coat 96-well microtitre plates. Wells were then incubated 
with 5% Normal Human Serum (NHS), and Human serum deficient (denoted as Δ) in C1q, mannose binding lectin 
(MBL), or factor B. Heated NHS and Gelatin Veronal Buffer (GVB) in place of serum were used as assay controls. The 
deposition of Factor B was detected with primary human specific antibodies, followed by horse radish peroxidase-
conjugated secondary antibodies, and the resulting colourmetric change of o-phenylenediamine measured at 490 nm. 
Results are reported as means ± SEM from three independent experiments with each sample performed in duplicate for 
each assay. Fluorescence of GVB in place of serum samples was subtracted as background for analysis.  
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3.5   Determining if scabies mite complement inhibitors interfere with the 
phagocytosis of S. pyogenes 88-30 
 
The experimental data reported in Results section 3.2 clearly revealed that scabies mite 
complement inhibitors SMIPP-S I1 and SMS B4 reduced the formation of the C3 convertases 
and disrupted the opsonisation of S. pyogenes 88-30 (Figures 10 and 11). It is possible that 
consequently in the presence of mite complement inhibitors the ability of granulocytes to 
phagocytose S. pyogenes will also be reduced. The potential of the scabies mite complement 
inhibitors, SMIPP-S I1 and SMS B4 to inhibit complement mediated phagocytosis of S. 
pyogenes was examined using flow cytometry to measure the phagocytosis of S. pyogenes by 
freshly purified human neutrophils labelled with Fluoresein isothiocyanate (FITC). 
 
3.5.1 FITC labelling of S. pyogenes 88-30 
 
As detailed in Materials and Methods section 2.5.1., a suspension of S. pyogenes 88-30 was 
labelled with Fluorescein isothiocyanate (FITC), a fluorochrome which fluoresces when 
excited with 495 nm of light. Using a GE Healthcare DeltaVision Deconvolution microscope, 
the FITC labelling was confirmed to be successful (Figure 19). 
 
Figure 19. Fluorescein isothiocyanate (FITC) labelled S. pyogenes 88-30 visualised by fluorescent 
microscopy. S. pyogenes 88-30 was incubated at 37oC, 5% CO2 / 95% air for 4 hours, then washed 3 times in carbonate 
buffer before diluting to approximately 1x108 cfu/ml in fresh carbonate buffer. Fluorescent labelling of GAS cells was 
performed by 1 hr aerobic incubation at 37oC in 0.1% FITC solution. Excess FITC was removed by washing in carbonate 
buffer three times. This image was produced by diluting the resulting FITC labelled GAS 88-30 suspension 1:100 and 
visualising the sample using a GE Healthcare DeltaVision Deconvolution microscope to measure light emission at 530 
nm. The image shown was captured at X1000 magnification. 
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3.5.2 Isolation of human neutrophils from healthy donor blood by gradient centrifugation 
 
Human neutrophils were isolated from freshly collected healthy donor blood, using differentia l 
gradient centrifugation. The concentration of isolated cells was estimated using a 
haemocytometer and the purity of the preparation was analysed by a FACS Canto A flow 
cytometer per Material and Methods section 2.5.4. 
 
 
 
The purity of the neutrophils as measured by FACS Canto A Flow cytometer was found to be 
approximately 60%. Figure 20 is representative of two independent isolations. The gated 
populations of cells (P1 and P2) represent the expected size range of neutrophils (P1) and the 
expected intracellular complexity of neutrophils (P2).  
 
3.5.3 Phagocytosis assay of S. pyogenes by human neutrophils 
The effect of scabies mite complement inhibitors versus BSA on the phagocytosis of S. 
pyogenes by human neutrophils, was determined with a flow cytometer per Materials and 
Methods section 2.5.6. 
 
 
 
 
 
 
Figure 20. Characterisation of gradient centrifugation isolated human neutrophils by flow cytometry 
Human neutrophils were isolated from fresh healthy  human donor blood by differential centrifugation. Neutrophil 
viability and cell concentration was determined by trypan blue staining, using a haemocytometer. The purity of the 
neutrophil preparation was determined by flow cytometry. Results are reported as the trend from two independent 
neutrophil isolations. 
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These findings show that very little FITC labelled S. pyogenes 88-30 were phagocytosed by 
the freshly prepared neutrophil preparation (Figure 21). Minor differences were observed 
between the SMS B4 and control treatments. To confirm that the FITC labelled bacteria could  
be detected by flow cytometry, this experiment was repeated per Material and Methods section 
2.5.6, with a greater concentration of bacteria; using a ratio of 50 bacteria to each neutrophil.  
 
Figure 21. Effect of scabies mite complement inhibitor SMS B4 on phagocytosis of 10 6 cfu GAS  88-30                                                                                                                                                                                                               
The phagocytosis of FITC labelled S. pyogenes 88-30 by freshly purified human neutrophils was determined in 10% 
normal human serum, pre-treated by aerobic incubation for 30 min at 37oC, 200 rpm with 0.4 µM Bovine Serum 
Albumin (BSA) (B) or 0.4 µM mite complement inhibitor SM S B4 (C). Heated serum + 0.4 µM BSA (A) was used as 
a negative control. The reaction was incubated aerobically at 37oC, 200 rpm; stopped after 40 min with 4% 
paraformaldehyde, and subsequently analysed with a FACS Canto A flow cytometer, measuring the fluorescence of 105 
gated neutrophils at 530 nm. Results are reported as the trend percentage of FITC positive and FITC negative cells from 
two independent assays. 
 
A B 
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The repeated analysis reported here (Figure 22) indicates that there were detectable levels of 
FITC labelled S. pyogenes 88-30 phagocytosis by neutrophil, however there was very little 
difference between the samples containing differently treated serum. The neutrophil purity was 
found to be only 60% (Figure 20), which was suboptimal. 
 
 
Figure 22. Effect of scabies mite complement inhibitor B4 on phagocytosis of 5x10 6 cfu GAS 88-30                                                                                                                                                                                                                              
The phagocytosis of fluorescein isothiocyanate (FITC) labelled S. pyogenes 88-30 by freshly purified human neutrophils 
was determined in 10% normal human serum, pre-treated by aerobic incubation for 30 min at 37oC, 200 rpm with 0.4 
µM Bovine Serum Albumin (BSA) (B) or 0.4 µM mite complement inhibitor SMS B4 (C). Heated serum + 0.4 µM BSA 
(A) was used as a negative control. The reaction was incubated aerobically at 37oC, 200 rpm; stopped after 40 min with 
4% paraformaldehyde, and subsequently analysed with a FACS Canto A flow cytometer, measuring the fluorescence of 
105 gated neutrophils at 530 nm. Results are displayed as Histograms reporting the trend percentage of FITC positive 
and FITC negative cells from two independent assays. 
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Optimising the isolation of human neutrophils using an immunomagnetic negative selection 
To improve the purity a second isolation technique was trialled using the Easy Step Direct 
Human Neutrophil Isolation kit (Stem Cell Technologies) per Materials and Methods section 
2.5.3.  
 
3.5.4 Immunomagnetic isolation of neutrophils from healthy human donor blood 
 
Human neutrophils were isolated from freshly collected healthy donor blood, using 
immunomagnetic negative selection per Materials and Methods section 2.5.3. The 
concentration of isolated cells was estimated using a haemocytometer and the purity of the 
preparation analysed by FACS Canto A flow cytometer per Material and Methods section 
2.5.4. The results of this procedure are shown in Figure 23.  
 
 
 
Figure 23. Characterisation of immunomagnetic isolated human neutrophils by flow cytometry                             
Human neutrophils were isolated from fresh healthly donor blood by immunomagnetic negative selection – using an 
EasySep Direct Human Neutrophil Isolation kit per manufacturer’s instructions. Neutrophil viability and cell 
concentration was determined by trypan blue staining, using a haemocytometer. The purity of the neutrophil preparation 
was determined by flow cytometry . These data are representative of 2 independent isolation experiments. 
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The purity of the neutrophils as measured by FACS Canto A flow cytometer was found to be 
approximately 95%. This data (Figure 23) is representative of two independent isolations. The 
gated populations of cells (P1) represent the expected size of neutrophils (x-axis) and 
intracellular complexity (y-axis) of neutrophils. The histogram displays the number of cells 
and intensity of auto-fluorescence of isolated neutrophils corresponding to the FITC signal. To 
verify that neutrophils were isolated, the CD66b marker expressed on peripheral neutrophils 
was probed with a mouse anti-human CD66b antibody conjugated to FITC per Materials and 
Methods section 2.5.5. 
 
 
Figure 24. Detection of the granulocyte marker CD66b on isolated human neutrophils                             
Human neutrophils were isolated from fresh healthy donor blood by immunomagnetic negative selection – using an 
EasySep Direct Human Neutrophil Isolation kit per manufacturer’s instructions. Neutrophil viability and cell 
concentration was determined by trypan blue staining, using a haemocytometer. The purity of the neutrophil preparation 
was determined by flow cytometry. Neutrophils were washed in Phosphate Buffered Saline (PBS), before being 
resuspended in PBS at a concentration of 107 cells per ml. A 20 µL aliquot of FITC mouse Anti-human CD66b (Becton 
Dickinson, USA) was added to a 100 µL volume of neutrophils (containing approximately 106 cells) and left on ice for 
20 min. The neutrophils were washed in PBS 3 times and were resuspended in 500ul PBS and the purity determined 
using flow cytometry. 
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The purity of the neutrophils as measured by the detection of CD66b by FACS Canto A flow 
cytometer was found to be approximately 98% (Figure 24). This data is representative of two 
independent isolations. The gated populations of cells (P1) represent the expected size of 
neutrophils (x-axis) and intracellular complexity (y-axis) of neutrophils.  Cell gate (P2) 
displays the expected intracellular complexity (x-axis) over the neutrophils considered positive 
for the FITC signal (y-axis). The histogram displays the intensity of isolated neutrophils 
positive for the FITC signal (x-axis) over the number of cells corresponding to the intensity of 
the FITC signal. 
 
3.6 Statistical analysis 
The statistical tests used to analyse the experimental data in this study included Two-way 
ANOVA with Dunnett’s or Sidak’s multiple comparisons test. Two-way ANOVA is 
appropriate for this study type as the experiments have been designed to measure the effect on 
a dependent variable – in the case of the bactericidal assays in Results section 3.1, the bacterial 
recovery by two independent factors; sample treatment and the concentration of the molecules 
used in the treatment. Dunnett’s test is relevant for determining the statistical significance of 
differences between the means of each individual sample treatments to the means of a control. 
Here this has been used to analyse Figure 8, in which the means of treatment groups; BSA, 
SMIPP-S I1 and SMS B4, were compared to the GVB control means. Sidak’s test was selected 
for data sets to compare the means between all treatment groups in the assay, for example the 
complement deposition assays in Results section 3.2 and 3.3, in which the mean measurements 
of equal concentrations of BSA treatment was compared against the mean measurements of a 
scabies complement inhibitor treatment. The significance threshold of all comparison tests 
were set to 5% or a p-value of 0.05. 
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The ability of the individual to rapidly detect and destroy invading pathogens is critical to the 
recovery of the organism. The complement component of the innate immune system is an 
effective first line defence system, tagging pathogens for phagocytosis, and/or directly lysing 
the cell. Pathogenic organisms have evolved sophisticated mechanisms to inhibit complement 
mediated immune responses (Meri et al., 2013; Pearce et al., 1990; Tyson et al., 2007). 
Streptococcus pyogenes (or group A Streptococcus (GAS)), a major bacterial pathogen in 
humans, produces an assortment of virulence factors to disrupt various stages of the 
complement cascade (Fernie-King et al., 2001; Lei et al., 2001; Podbielski et al., 1996; Thern 
et al., 1995; von Pawel-Rammingen & Bjorck, 2003). Similarly, scabies mites have been 
reported to produce a large range of secretory proteins, including multiple families of proteases 
and protease inhibitors that disrupt the human complement system (Bergstrom et al., 2009; 
Mika et al., 2012a; Mika et al., 2012b; Reynolds et al., 2014; Swe & Fischer, 2014).  
Using immunohistochemistry approaches, previous research has shown that scabies mite 
complement inhibitors are localised within the mite gut and are excreted into the epidermal 
burrows with the mite faeces (Mika et al., 2012a; Willis et al., 2006). One of their likely 
functions has been proposed to avert gut damage due to complement-mediated immune 
processes; as the mite has been shown to feed on host serum (Rapp et al., 2006) and human 
complement components have previously been localised in the mite gut (Mika et al., 2011). 
Within epidermal burrows of the scabies mite, the release of multiple anti-complement proteins 
may act synergistically and amount to levels that effectively inhibit complement activity 
locally. As a consequence, this may provide a favourable environment for the establishment of 
secondary bacterial infections in scabies burrows. GAS is an opportunistic pathogen that is 
endemic in many regions of Northern Australia, a major cause of skin disease that often 
coincides with or follows the onset of scabies (Clucas et al., 2008; Currie & Carapetis, 2000). 
The association of scabies and bacterial pyoderma forms the basis of my hypothesis; that 
scabies infections cause local complement inhibition in the epidermal burrows of its host, 
promoting the establishment of opportunistic pathogens such as GAS. 
The scabies mite complement inhibitors SMIPP-S I1 and SMS B4 have been reported to 
promote the in vitro growth of a single GAS M1 strain (Mika et al., 2012a). More recently, 
SMS B4 has also been shown to promote the growth of a range of Staphylococcus aureus 
strains, isolated from patient skin infections in Queensland and the Northern Territory (Swe & 
Fischer, 2014). The results presented here provide further evidence that SMIPP-S I1 and SMS 
B4 both promote the growth of S. pyogenes. The data reported here has expanded from the 
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previous study by including various GAS clinical isolates from all three emm-pattern types. 
Pattern A – C strains predominantly cause throat infections, pattern D predominately cause 
skin infections and Pattern E strains are reported to cause both skin and throat infections. The 
viability of all GAS strains was significantly increased in whole human blood treated with 
SMIPP-S I1 and SMS B4 suggesting that this effect is not strain specific. As the complement 
response is non-specific (Frank & Fries, 1991), this result was expected and these data show 
the same trend as earlier studies into the effect of SMIPP-S I1 and SMS B4 on the viability of 
different bacterial isolates to those examined here (Mika et al., 2012b; Swe & Fischer, 2014).  
By focusing only on GAS 88-30, originally isolated from a scabies patient in the Northern 
Territory (Brandt et al., 2000; CDC, 2014), it was shown that SMIPP-S I1 and SMS B4 both 
reduce the blood mediated killing of GAS in a concentration dependent manner.  
Bergstorm et al. and Mika et al. reported previously that SMIPP-S I1 and SMS B4 interfere 
with the initiation and progression of all three complement pathways (Bergstrom et al., 2009; 
Mika et al., 2012a). However, these studies assessed the human complement activation, using 
homogenous artificial substrates such as zymosan, mannan or human IgG to activate the 
Alternative, Lectin and Classical complement pathways respectively. To address the effect of 
mite complement inhibitors on complement activation on the bacterial surface it was necessary 
to accurately reflect the heterogeneous makeup of the bacterial cellular surface. Therefore 
whole GAS cells were used to activate complement in the experiments presented here. Since 
SMIPP-S I1 and SMS B4 belong to different classes of mite complement inhibitors, namely 
serine proteases and serpins, it was postulated and shown that these molecules are likely to 
impact at different steps of the complement cascade (Mika et al., 2012a; Reynolds et al., 2014). 
This was also reflected in the results presented here – in the differences in the amount of 
bacterial recovery induced by the two complement inhibitors as well as in the IC50 values in 
the complement deposition assays. The IC50 of SMIPP-S I1 required for the reduction of 
complement deposition on GAS was approximately 10-fold higher than that of SMS B4. In 
these regards SMS B4 appeared to be a more potent inhibitor of complement components 
required for neutralisation of GAS than SMIPP-S I1 and it is more likely that SMIPP-S I1 is 
less advantageous to the bacteria. This complement inhibitor has been proposed to play a key 
role in protecting the scabies mite itself; as MBL, the primary activator of the Lectin pathway 
has been found to bind to the lining of the mite gut (Mika et al., 2011) and SMIPP-S I1 has 
been shown to specifically interfere with the Lectin Pathway (Reynolds et al., 2014). 
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Both SMIPP-S I1 and SMS B4 increased the deposition of C1q, the pattern recognit ion 
molecule that initiates the Classical pathway, on the surface of GAS. The effect I have observed 
here appears to be marginal; with C1q deposition increased by approximately 5% at 4 µM of 
SMIPP-S I1, and approximately 10 – 20% between 2 µM – 4 µM of SMS B4 respectively 
(Figure 13, section 3.3.1). This requires further investigation, as previous findings have 
demonstrated that SMS B4 decreased C1q deposition (Bergstrom et al., 2009; Mika et al., 
2012a). More recently, a similar study on SMS B4 reported a slight increase in C1q deposition 
on Staphylococcus aureus similar to the levels observed here (Swe & Fischer, 2014). One 
potential advantage in increasing C1q levels for the scabies mite and inadvertently for 
associated bacterial pathogens, is highlighted in research by Potempa et al. (2009) where C1q 
deposition was also found to be marginally increased during the initial stages of bacterial 
infections. The authors have suggested this may lead to a low grade inflammation that is 
beneficial to the pathogen by increasing the availability of nutrients and growth factors 
produced during innate immune process and promoted bacterial colonisation (Potempa et al., 
2009).  Both SMIPP-S I1 and SMS B4 reduced C4b deposition on the cellular surface of S. 
pyogenes in this study, indicating that these proteins reduce with the amount of C3 convertase 
(C4b2a) formed in the Classical and Lectin pathways. However, it is likely that only the C3 
convertases of the Classical pathway is involved in this case, as I did not detect MBL on the 
GAS surface. This finding suggests that the mechanism by which SMIPP-S I1 and SMS B4 
reduce C4b deposition, is via disruption of the Classical pathway activation. Since C1q 
deposition was found to be slightly increased, it is possible SMS B4 and SMIPP-S I1 are 
affecting the function of C1 complex, namely cleavage of C4 to C4a and C4b, without affecting 
the interaction of the C1 complex with the cell surface. I discuss a potential experiment to 
investigate the effect of SMS B4 on C1q and the C1 complex in the “Conclusions and future 
directions” section.  
It has been reported previously that the Classical and Alternative pathways are the primary 
innate immune response to S. pyogenes and other Streptococci (Brown et al., 2002; Wessels et 
al., 1995; Yuste et al., 2006). Likewise, under our assay conditions, MBL did not bind to the  
surface of S. pyogenes 88-30, suggesting that the MBL-dependent Lectin pathway is not 
activated. It has previously been reported that L-ficolin, a pattern recognition molecule also 
capable of activating the Lectin pathway, specifically detects Lipoteichoic acid; a cell wall 
component present in all gram positive bacteria, including S. pyogenes (Lynch et al., 2004). 
Thus the Lectin pathway may house additional roles in the complement response to S. 
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pyogenes. Both SMIPP-S I1 and SMS B4 were found to significantly reduce the binding of 
properdin to S. pyogenes 88-30, as shown in Figure 14 of results section 3.3.1. The role of 
properdin is to stabilise the C3 convertase (C3bBb) of the Alternative pathway, therefore a 
reduction in properdin deposition may result in a decreased level of C3 convertase formation 
in the Alternative pathway. C3 convertase formation in the Alternative pathway is initiated by 
the deposition of C3b from spontaneous hydrolysis of basal C3 levels. If the scabies mite 
complement inhibitors are directly interfering with the cleavage of C3 into C3a and C3b, 
consequently the reduction in C3 convertase formed in the Alternative pathway will be 
amplified. Properdin has also been found to act as a pattern recognition molecule to activate 
the Alternative pathway independently (Bowen et al., 2014; Kobayashi & DeLeo, 2009; 
Mounsey et al., 2010). This latter fact may also be relevant for complement activation to 
scabies mite surface components, which may explain why SMIPP-S I1 and SMS B4 have 
evolved to inhibit properdin binding. 
Reduced C3 convertase formation on the surface of GAS resulted in a reduction in the level of 
C3b on GAS (Figure 11, Results section 3.2). C3b is the key opsonin which marks pathogens 
for phagocytosis and once high concentrations are reached, initiates the formation of the C5 
convertase. The inhibition of C3b deposition may in turn reduce the level of C5 convertase, 
leading to a decreased production of the anaphylatoxin C5a, which plays a critical role in 
attracting phagocytes to the site of infection. These results support previous findings with 
SMIPP-S I1 and SMS B4 in which similar levels of disruption to the formation of the C3 
convertase (Bergstrom et al., 2009; Mika et al., 2012a; Mika et al., 2012b; Swe & Fischer, 
2014) and the C5 convertase (Swe & Fischer, 2014) were reported. 
In Results section 3.4 I aimed to determine which pathway(s) of the human complement is 
most critical for the host response to GAS. The data overall indicate that a deficiency in the 
C1q component of the Classical pathway led to the greatest reduction in opsonisation of GAS. 
Figure 15 (section 3.4) suggested that a deficiency in MBL resulted in the highest reduction of 
C3b deposition, however the addition of heated human serum with high levels of GAS 
antibodies recovered the level of C3b deposition to a similar level as seen when NHS was tested 
in a control assay. The MBL deficient serum was then found to contain an excessive C1q 
concentration of 160% compared with the NHS, as reported in Figure 16, suggesting antibody 
dependent activation of complement is most important in the activation of complement to S. 
pyogenes. Interestingly, the level of C3b deposition in the C1q deficient serum sample was also 
recovered following addition of heated human serum with high levels of S. pyogenes antibodies 
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in Figure 16. This result is unexpected, though there is a potential explanation for this result. 
While it is well-established that antibody-dependent activation of complement occurs by the 
Classical pathway, antibody-dependent activation of the Alternative pathway has been reported 
for several disease processes in humans and animals with C1q deficiencies (Banda et al., 2007; 
Cutler et al., 1991; Zhou et al., 2012). The Alternative pathway is known to amplify both the 
Classical and the Lectin pathways, thus it is possible that the antibody-directed properdin-
activation of complement occurs when the Classical pathway is absent or non-functional.  
Complement-mediated immune responses facilitate the killing of pathogens via phagocytos is, 
or via direct cell destruction by the formation of the membrane attack complex. The latter 
process is ineffective against gram positive bacteria, due to the structural composition of the 
cell wall (Berends et al., 2013; Joiner et al., 1983). Therefore, the recovery of the GAS clinica l 
isolates observed in this study is most likely due to interference with phagocytosis. Neutrophils 
are the most abundant human leucocyte, and play an essential role in complement mediated 
phagocytosis (Kobayashi & DeLeo, 2009). An additional aim of this study was to determine if 
SMIPP-S I1 and SMS B4 interfere with the phagocytosis of S. pyogenes by neutrophils. The 
methods used to generate the preliminary data (section 3.5) are based on a similar study 
investigating the effect of SMS B4 on the phagocytosis of S. aureus by neutrophils (Swe & 
Fischer, 2014). The method for GAS phagocytosis assay is currently being optimised. As the 
negative control experiment contains heat inactivated serum, very little phagocytosis should be 
observed, however a FITC signal indicating phagocytosis was observed, suggesting that this 
control experiment requires optimisation, most likely with regards to the concentrat ion of FITC 
labelled bacteria. An additional consideration is that the purity of neutrophils obtained by 
gradient centrifugation (60%; as shown in Figure 20, Results section 3.5.2) was lower than that 
used in the study by Swe and Fischer (2014), in which a minimum neutrophil purity of 70% 
was considered necessary. This method required a significant amount of time and neutrophils 
are short lived once isolated from the host, with an estimated viability of up to 4 hours (Oh et 
al., 2008). The time taken and the process involved in gradient centrifugation may have 
activated or damaged the neutrophils, reducing viability and functionality. The purity of the 
neutrophils obtained using immunomagnetic negative selection was considerably higher, at 
95%, as reported in results section 3.5.4. Due to time limitations, I was not able to repeat the 
assays with neutrophils isolated using this method. In the future it would be beneficial to ensure 
that the viability and functionality of the neutrophils is maintained following immunomagnetic 
isolation, using techniques such as the oxidative burst test (Hashiguchi et al., 2005). There may 
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also be differences in the time required for the neutrophils to phagocytose S. pyogenes, 
compared to S. aureus; 40 minutes was selected here based on the conditions in the Swe and 
Fischer (2014) study, which investigated phagocytosis of S. aureus. It will be beneficial to 
measure the level of FITC-GAS phagocytosis over a time course, to ensure the optimal time is 
selected. 
The findings reported in this study provides supportive data for the hypothesis that disruption 
of complement mediated immune responses to scabies provide favourable conditions not only 
for scabies mites themselves to survive and proliferate in the host, but also for bacteria that 
colonise the mite infected epidermis. Consequently GAS pyoderma may be promoted by the 
presence of mites and may in unfortunate circumstances progress to an invasive state leading 
to systemic bacteraemia. The ability of S. pyogenes infection to become systemic may induce 
an adaptive immune response, priming the host immune system for secondary sequelae such 
as rheumatic heart disease in susceptible individuals. A recent study by Ellis et al. (2010) has 
suggested that individuals susceptible to rheumatic heart disease may possess similar cardiac 
myosin epitopes that share structural similarities with group A streptococcal surface 
components found across all emm types (Ellis et al., 2010). According to their findings, any S. 
pyogenes infection that is persistent enough to induce human antibody responses that cross 
react with host tissue epitopes may have the potential to lead to rheumatic fever and rheumatic 
heart disease. Instances where this scenario has been identified have been published. For 
example, a recent study in Hawaii, where rheumatic heart disease occurs at one of the highest 
rates worldwide, reported that the GAS emm types implicated in the development of ARF in 
Hawaii were not among the so-called rheumatogenic emm types found in temperate climates 
(Erdem et al., 2007). This suggests that different GAS emm types may be capable of inducing 
rheumatic fever and rheumatic heart disease between temperate and tropical climates. This 
notion has been suggested by several research groups (McDonald et al., 2007; McDonald et 
al., 2004; Parks et al., 2012). The current hypothesis in the literature is that GAS pyoderma 
may be responsible for the high rates of rheumatic heart disease observed in tropical climates, 
in accord with the low reported rates of GAS pharyngitis. In tropical regions of Australia and 
the Pacific, GAS pyoderma is implicated as the primary cause of invasive GAS disease 
(Carapetis et al., 1999; Le Hello et al., 2010; Romani et al., 2015). Scabies is recognised as a 
major risk factor for pyoderma in Aboriginal communities of tropical northern Australia 
(Clucas et al., 2008; Currie & Carapetis, 2000; Kearns et al., 2013). The finding that SMIPP-
S I1 and SMS B4 promote the recovery of GAS and inhibit complement mediated responses 
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highlights the link between scabies and associated bacterial infections, emphasizing that urgent 
attention is required towards scabies infections in these communities. Prevention and 
eradication of scabies may in turn reduce the heavy burden of pyoderma observed and 
potentially prevent the development of rheumatic fever and rheumatic heart disease. 
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Chapter 5: Conclusion 
and future directions 
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This study provides further evidence that SMIPP-S I1 and SMS B4 interfere with the human 
complement defence. SMIPP-S I1 and SMS B4 reduced the amount of C3 convertase formed 
on the surface of the bacteria and consequently reduced deposition of C3b, a potent opsonin on 
the surface of S. pyogenes. This in turn interfered with the complement-mediated neutralisa t ion 
of GAS. This study suggests that the function of the Classical and Alternative pathways are 
predominately effected by SMS B4 and SMIPP-S I1 in response to GAS.  
 
Limitations of study 
The above findings may not be the sole mechanisms of these scabies mite complement 
inhibitors in the pathogenicity of scabies associated bacterial infections. The potential effects 
of SMIPP-S I1 and SMS B4 on the ficolins and collectins in complement activation to GAS 
have not been addressed in this study, leaving the Lectin pathway for future investigat ion. 
There are additional controls that may be suitable for future repeats of the assays performed in 
this study, these include: heat inactivated serum as a positive control for anti-complement 
activity in bactericidal assays and heat inactivated scabies mite complement inhibitors to 
demonstrate the specificity of their activity. The anti-complement protein cobra venom factor 
has been used as a positive control in similar bactericidal assays to those performed in this 
study (Swe & Fischer, 2014), however the stock batches obtained recently have yielded 
inconsistent results and was left out of the study due to time restrictions. Cobra venom factor 
is also not suitable for use in the ELISA assays to measure the deposition of C3b as it is 
structurally homologous to C3b and has been found to cross-react with C3b antibodies (Vogel 
et al., 1984). Additionally, the number of samples and time available to perform all assays in 
this study is limited due to the use of human blood and blood products that expire within a 
relatively short time frame. Therefore it was not feasible to include these additional controls in 
this study. 
This study has investigated the activity of two recombinant scabies mite complement inhibito rs 
within an in-vitro system. The artificial assay systems used here will not entirely represent the 
complex in vivo conditions during scabies infestation and subsequent secondary bacterial 
infections in the skin. Likely the percentage of biologically active molecules is not 100% in the 
preparations of recombinantly produced proteins. In addition, during an active scabies 
infection, it is likely that mite complement inhibitors are not produced in isolation. SMIPPS-
I1 and SMS B4 are members of two multi-copy families of predicted protein homologs 
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discovered previously in a gene discovery project analysing scabies mite mRNA transcripts 
(Fischer et al., 2003). It is very likely that multiple homologous proteins of each family are 
expressed simultaneously by multiple mites present within the skin burrows. While the in vivo 
concentrations of these molecules in the mite gut is unknown,  a cumulative effect of many 
anti-complement activities coming from the large family of SMIPP-Ss and from at least two if 
not more serine protease inhibitors is most likely. As many of these molecules may act on 
several levels in the complement system.  
 
Future directions 
The finding that SMS B4 slightly increased the deposition of C1q on the surface of 
Staphylococcus aureus (Swe & Fischer, 2014) and now GAS (reported in Figure 13, Results 
section 3.3.1) are conflicting observations with previous studies which have demonstrated that 
SMS B4 decreased C1q deposition (Bergstrom et al., 2009; Mika et al., 2012a). A potential 
experiment to determine the functional effect(s) of SMS B4 on C1q deposition, is to investiga te 
if formation of the activated C1 complex is disrupted, by performing a C1 reconstitution assay 
as described by (Arlaud & Thielens, 1993) in the presence of SMS B4 or controls. By treating 
assay samples with SMS B4 or controls and performing SDS-PAGE on the resulting reaction 
mixtures, it is possible to determine if SMS B4 prevents the conversion of the C1 complex 
proenzymes C1r and C1s to their active forms. The active forms of C1r and C1s are functiona l 
serine proteases resulting in the downstream progression of the Classical pathway, by 
catalysing the cleavage of C4 to C4a and C4b.  Activated forms of these complement factors 
will produce two distinct protein bands each of 57 and 35 kDa (C1r) and 55 and 30 kDa (C1s), 
while the inactivated proenzymes will be visible as single 85 kDa (C1r) and 84 kDa (C1s) 
bands by SDS PAGE respectively. A western blot could also be performed to be more confident 
in the differential identification of these molecules. 
The functional analysis of the two recombinant scabies mite protein reported here may very 
likely not completely reflect the natural pathogenesis. Further research is required to elucidate 
the collective roles of complement inhibitors released during the scabies infection. It has been 
shown that secondary bacterial infections of the mite burrows often involve co-infections of 
both S. pyogenes and S. aureus (Bowen et al., 2014; Steer et al., 2009; Whitehall et al., 2013). 
It would be ideal to extend the work from earlier studies and here, to include combinations of 
mite complement inhibitors in the same assay at lower concentrations. Human scabies samples 
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are very difficult to obtain. The porcine integumentary system closely resembles that of human, 
and since 2010 a porcine model of scabies has allowed for complete study of the mite lifecyc le 
and disease process (Mounsey et al., 2010). Using this model it may be possible to both extend 
the bactericidal assays to an in vivo platform, and also to utilise transcriptome based methods 
to identify the presence and population of scabies mite complement inhibitors released during 
the disease process. As recently shown in this porcine model (Swe et al., 2014) scabies 
infections have a significant effect on the composition of the cutaneous microbiome. 
Investigating the potential of scabies induced microbiome changes in humans should be high 
on the future research agenda, despite the challenges of limited access to scabies patients and 
ethical limitations with regards to longitudinal studies. Understanding whether the relationship 
between scabies mites and pathogens interferes with the dynamics of the host-benefic ia l 
microflora may provide further insights into the pathogenesis of scabies and associated 
bacterial disease. Investigation of the skin microbiome in scabies patients may reveal novel 
information including a novel diagnostic marker, as scabies infections are notoriously difficult 
to reliably diagnose by current methods (Walter et al., 2011).  
 
This study demonstrates that the scabies mite complement inhibitors SMIPP-S I1 and SMS B4 
interfere with the complement cascade, disrupting a critical component of the early stages of 
the host immune response, in turn providing an optimal environment for the establishment and 
proliferation of opportunistic pathogens such as Group A Streptococcus. The practical 
outcomes of this finding are that this knowledge invites furthers research as well as highlights 
the need for early intervention into scabies infections. Changes in policies and practices in this 
regard may ultimately prevent the onset of secondary bacterial infections and the potentially 
fatal downstream diseases that may result.  
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Growth curve results – for estimation of GAS cfu challenge dose. 
 
Time Dilution Counts per 10uL (GAS 88/30) Total Average Cfu/ml 
0 hrs 1:1000 22 17 20 24 18 20 121 20.2 2.02 x 106 
2 hrs 1:1000 31 29 32 30 33 26 181 30.2 3.02 x 106 
3 hrs 1:10000 20 16 17 15 16 18 102 17 1.70 x 107 
4 hrs  1:10000 26 27 23 19 27 20 142 23.7 2.37 x 107 
 
Time Dilution Counts per 10uL (GAS PRS55) Total Average Cfu/ml 
0 hrs  1:1000 20 18 22 17 18 21 116 19.3 1.93 x 10
6 
2 hrs 1:1000 26 36 28 29 33 25 177 29.5 2.95 x 10
6 
3 hrs  
1:10000 
14 15 12 20 15 19 95 15.8 1.58 x 107 
4 hrs  1:10000 20 20 17 22 25 18 122 20.3 2.03 x 10
7 
 
Time Dilution Counts per 10uL (GAS PRS15) Total Average Cfu/ml 
0 hrs  
1:1000 
14 17 20 20 18  17 106 17.7 1.77 x 106 
2 hrs  1:1000 32 28 25 27 30  22 164 27.3 2.73 x 10
6 
3 hrs  1:10000 15 16 15 11 18  13 88 14.7 1.47 x 10
7 
4 hrs  1:10000 17 19 16 22 24  20 118 19.7 1.97 x 10
7 
 
Time Dilution Counts per 10uL (GAS PRS30) Total Average Cfu/ml 
0 hrs  1:1000 18 14 20 17 18  16 103 17.2 1.72 x 10
6 
2 hrs  1:1000 22 26 28 22 29  26 153 25.5 2.52 x 10
6 
3 hrs  1:10000 17 14 11 16 17  13 88 14.7 1.47 x 10
7 
4 hrs  1:10000 23 18 24 19 22  26 132 22.0 2.20 x 10
7 
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Media and Solution Recipes 
All solutions were made up in sterile water and stored at room temperature (RT) unless 
otherwise stated. 
 
Ampicillin stock 
Ampicillin (Sigma, USA)                                                     100 µg/ml  
Filter sterilise, aliquot into 1 ml volumes and store at -20˚C 
 
Binding buffer (Cation exchange – SMIPP-S I1 purification) 
2-(N-morpholino)ethanesulfonic acid  (MES) (Sigma, USA)              50 mM 
Glycerol (Chem-supply, Australia)       10% 
Adjust to pH 5 and filter sterilise. 
 
Binding buffer (Hydrophobic interaction chromatography – SMIPP-S I1 purification) 
Ammonium sulphate (Scherlab S.L., Spain)                 1.5 M 
MES (Sigma, USA)                    10 mM 
Glycerol (Chem-supply, Australia)       10% 
Adjust to pH 5 and filter sterilise 
 
Block buffer (4% BSA in PBS with 0.05% Tween-20) 
Bovine serum albumin (Sigma, USA)                   4% (w/v) 
Tween-20 (Sigma, USA)                                              0.05%  
Aliquot into 50 ml volumes and store at -20˚C 
 
BMGY complete media (per L) 
BMGY base (see below)                   700 ml 
Potassium phosphate buffer (see below)                 100 ml 
Methanol 5% solution (see below)                   100 ml 
Glycerol 10% solution (see below)                                                                            100 ml 
Zeocin (Sigma, USA)                                                     500 µg/ml 
Mix well and store excess at 4˚C 
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Buffered glycerol complex yeast (BMGY) base media (per L) 
Yeast extract (Becton Dickinson, USA)      70 g 
Peptone (Becton Dickinson, USA)       140 g 
Autoclave solution and store at 4˚C 
 
Elution buffer (Cation exchange – SMIPP-S I1 purification) 
Sodium Chloride (NaCl) (Chem-supply, Australia)     0.4 M 
MES (Sigma, USA)                                                                50 mM 
Adjust to pH 5 and filter sterilise 
 
Carbonate buffer 
Sodium carbonate (Ajax finechem, Australia)     0.1 M 
Sodium bi-carbonate (Ajax finechem, Australia)     0.1 M 
Adjust to pH 9.6 and filter sterilise 
Store at 4˚C 
 
Coomassie Blue stain 
Coomassie Brilliant Blue R250 (BioRad, USA)                0.25% 
Methanol (Honeywell, USA)        50% 
Acetic acid (Merck KGaA, Germany)                 10% 
Dissolve ingredients and filter with Whatman number 1 filter paper (GE Life Sciences, USA) 
 
Coomassie destain 
Methanol (Honeywell, USA)        25% 
Acetic acid (Merck KGaA, Germany)                 7.5% 
 
Dithiothreitol (DTT) 1M 
DTT (Sigma, USA)         1.5 g 
Sterile water          10 ml 
Aliquot into 1 ml volumes and store at -20°C 
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Elution buffer (Cation exchange – SMIPP-S I1 purification) 
Sodium Chloride (NaCl) (Chem-supply, Australia)     0.4 M 
MES (Sigma, USA)                                                                50 mM 
Adjust to pH 5 and filter sterilise 
 
Elution buffer (SMS B4 purification) 
Urea (Sigma, USA)         6 M 
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA)             50 mM 
NaCl (Chem-supply, Australia)        500 mM 
DTT (Sigma, USA)         1 mM 
Imidazole (Sigma, USA)        250 mM 
Adjust to pH to 6 just before use 
 
Equilibration buffer (SMS B4 purification) 
Urea (Sigma, USA)         6 M 
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA)             50 mM 
NaCl (Chem-supply, Australia)       500 mM 
DTT (Sigma, USA)         1 mM 
Imidazole (Sigma, USA)        5 mM 
Gently heat to dissolve the Urea and adjust to pH 8 just prior to use 
 
Fluorescein isothiocyanate (FITC) Buffer 
FITC (Sigma, USA)                                                               100 mg/ml 
Make up in DMSO and store at -80°C in light protected tube.                                         
 
Gelatin veronal buffer (GVB) buffer (for 500 ml) 
VBS – see Veronal buffer                                             100 ml 
Gelatin  (Sigma, USA)                                          0.1% 
MgCl2 (Sigma, USA)                    1 mM 
CaCl2 (Ajax finechem, USA)                                         0.15 mM 
*Dissolve gelatin in VBS, mix in other ingredients, top up to 500 ml with dH20. Store at -20°C 
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Glycerol 10% (v/v) solution 1 L 
Glycerol (Chem-supply, Australia)                                                                            100 ml 
Sterile water                                                                                                                900 ml 
 
HBSS+HSA buffer 
Human serum albumin (Sigma, USA)                                                   0.1% 
Made up in 1X Hanks balanced salt solution (Life Technologies, Australia) 
 
Horse blood agar plates 
Columbia Blood Agar Base (Oxoid, USA)        30 g/L  
Autoclave and leave in a 55˚C water bath for approximately 3 hours.   
Once agar has reached 55˚C; add 2% defibrinated horse blood just before pouring plates (lysis 
of red blood cells may occur if the agar temperature is higher than 55˚C). Pour approximate ly 
20 ml per sterile tissue culture dish (100 x 20 mm) (Sarstedt, USA). Store plates at 4˚C 
 
Isopropylthio-B-D-galactoside (IPTG) 1 M 
IPTG (AppliChem GmbH, Germany)                  1 g 
Sterile water          4.2 ml 
Filter sterilise, Aliquot into 1 ml volumes and store at -20˚C 
 
Labelling buffer 
Bovine serum Albumin                                         0.5% 
EDTA (Sigma, USA)         2 mM 
Dissolve in Phosphate Buffered Saline (Life Technologies, Australia) and filter sterilise 
                        
Laemmlis sample buffer (4X) 
2M Tris-HCl pH 6.8 (see Tris-HCl 2M pH 6.8)     62.5 mM 
Sodium dodecyl sulphate (USB corporation, USA)     2% 
Bromophenol Blue (Oxoid, USA)       0.05% 
Glycerol (Chem-supply, Australia)       20% 
Β-mercaptoethanol (Sigma, USA)       0.71 mM 
Aliquot into 1 ml volumes and store solution at -20˚C. 
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LB agar plates 
As for LB media but before autoclaving add 
Agar (Becton Dickinson, USA)       15 g/L 
Adjust to 50˚C in water bath before adding antibiotics. Pour into petri dishes and store at 4˚C 
 
 
LB media (per L) 
Tryptone (Becton Dickinson, USA)       10 g 
Yeast extract (Becton Dickinson, USA)      5 g 
NaCl (Chem-supply, Australia)       10 g 
Autoclave solution 
 
Methanol 5% (v/v) solution (L) 
Methanol (Honeywell, USA)        5 ml 
Sterile water          950 ml 
               
Phosphate buffer 
1M Potassium dihydrogen orthophosphate (Merck KGaA, Germany)  868 ml 
1M di-Potassium hydrogen orthophosphate (Merck KGaA, Germany)             132 ml 
Adjust to pH 6 and autoclave 
 
Refolding buffer 
Arginine (Sigma, USA)        300 mM 
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA)             50 mM 
NaCl (Chem-supply, Australia)                                        500 mM 
DTT (Sigma, USA)                               5 mM 
Adjust to pH to 10.5 just before use 
 
SDS-PAGE separating buffer 
2M Tris-HCl pH 8.8 (see Tris-HCl 2M pH 8.8)     75 ml 
10% SDS (see SDS – 10%)                                            4 ml 
Sterile water          21 ml 
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SDS-PAGE stacking gel buffer 
1M Tris-HCl pH 6.8         50 ml 
10% SDS (see SDS – 10%)                                                 4 ml 
Sterile water          46 ml 
 
SDS running buffer (1X) 
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA)             3.03 g 
Glycine (Chem-supply, Australia)       1.44 g 
Sodium dodecyl sulphate (USB corporation, USA)     1 g 
Sterile water                                                                                                             1 L 
 
Serpin buffer  
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA)             50 mM 
EDTA (Sigma, USA)         10 mM 
NaCl (Chem-supply, Australia)       100 mM 
Adjust to pH 8 
 
Serpin buffer + Triton X100 buffer 
As serpin buffer, but add 0.5% (w/v) Triton –X100 (Sigma, USA) 
 
Silver stain fixing solution 
Methanol (Honeywell, USA)        50% 
Acetic acid (Merck KGaA, Germany)      10% 
Fixative Enhancer (BioRad, USA)                  10% 
Sterile water          30% 
 
Silver stain solution A 
Development Accelerator Solution (BioRad, USA)                5% (w/v) 
Mix in dH2O to dissolve powder. Prepare immediately before use 
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Silver stain solution B 
Silver Complex Solution (BioRad, USA)                 10%  
Reduction Moderator Solution (BioRad, USA)                10% 
Image Development Reagent (BioRad, USA)                10%  
Sterile water          70%  
Mix solutions A and B in a 1:1 ratio immediately before use 
 
Silver stain stop solution 
Acetic acid (Merck KGaA, Germany)      5%  
Sterile water          95% 
 
SMIPP elution buffer 1 (Hydrophobic interaction chromatography) 
Ammonium sulphate (Merck KGaA, Germany)     1.0 M 
MES (Sigma, USA)                    10 mM 
Glycerol (Chem-supply, Australia)       10% 
Adjust to pH 5 and filter sterilise 
 
SMIPP elution buffer 2 (Hydrophobic interaction chromatography) 
As SMIPP-S elution buffer 1, except Ammonium sulphate              0.5 M 
 
SMIPP Elution buffer 3 (Hydrophobic interaction chromatography) 
As SMIPP-S elution buffer 1, except Ammonium sulphate   0 M 
 
SMIPP equilibration buffer (Hydrophobic interaction chromatography) 
Ammonium sulphate (Merck KGaA, Germany)                1.5 M 
MES (Sigma, USA)                    10 mM 
Glycerol (Chem-supply, Australia)       10% 
Adjust to pH 5 and filter sterilise 
 
SMIPP dialysis buffer 
MES (Sigma, USA)                                          50 mM 
Glycerol (Chem-supply, Australia)       10% 
Adjust to pH 5 
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Sodium Docecyl Sulphate (SDS) 10% 
Sodium dodecyl sulphate (USB Corporation, USA)     10 g 
Sterile water          100 ml 
Heat to 68˚C, adjust to pH 7.2  
 
Solubilisation buffer 
Guanidinium HCl (Sigma, USA)                   6 M 
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA)   50 mM 
Adjust to pH 7.8 
 
Todd Hewitt Broth (THB) 
Todd Hewitt Broth Base (Oxoid, UK)                                                  36.4 g 
Sterile water          1 L 
Adjust pH to 6.8 with HCl 
 
Tris-HCl 1M 
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA)             12.1 g 
Sterile water          100 ml 
Adjust pH to 6.8 with HCl 
 
Tris-HCl 2M pH 6.8 
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA) 24.2 g 
Sterile water          100 ml 
Adjust pH to 6.8 with HCl 
 
Tris-HCl 2M pH 8.8 
Sigma 7-9 (2-Amino-2-(hydroxylmethyl)-1,3-propanediol) (Sigma, USA)             24.2 g 
Sterile water          100 ml 
Adjust pH to 8.8 with HCl 
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Veronal buffer saline (VBS) -Make 1L  
NaCl (Chem-supply, Australia)                             720 mM 
Na-barbital (Sigma, USA)        9.0 mN 
Barbituric acid  (Sigma, USA)                   15.5 mM 
*VBS stock is used to make up other buffers such as GVB 
 
Wash buffer (PBS-tween) 
1X PBS (Life Technologies, Australia)      1 L 
Tween-20 (Sigma, USA)        500 µl 
 
Yeast nitrogen base solution (per L) 
Yeast Nitrogen base (Becton Dickinson, USA)                134 g 
Filter sterilise and store at 4˚C 
 
2YT media 
Tryptone (Becton Dickinson, USA)       16 g 
Yeast extract (Becton Dickinson, USA)      10 g 
NaCl (Chem-supply, Australia)       5 g 
Sterile water          1 L 
Autoclave and store at 4˚C 
 
